<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000204.pub2" GROUP_ID="SCHIZ" ID="461799082414364395" MERGED_FROM="" MODIFIED="2018-01-17 14:06:12 +0000" MODIFIED_BY="Claire Irving" REVIEW_NO="13" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0"><COVER_SHEET MODIFIED="2018-01-17 14:06:11 +0000" MODIFIED_BY="Claire Irving"><TITLE MODIFIED="2016-10-13 14:18:15 +0100" MODIFIED_BY="[Empty name]">Anticholinergic medication for antipsychotic-induced tardive dyskinesia</TITLE><CONTACT MODIFIED="2018-01-17 14:06:11 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="59249928586857976988110908155847" ROLE="AUTHOR"><FIRST_NAME>Hanna</FIRST_NAME><LAST_NAME>Bergman</LAST_NAME><EMAIL_1>hbergman@cochrane.org</EMAIL_1><EMAIL_2>behanna@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Cochrane Response</DEPARTMENT><ORGANISATION>Cochrane</ORGANISATION><ADDRESS_1>St Albans House</ADDRESS_1><ADDRESS_2>57-59 Haymarket</ADDRESS_2><CITY>London</CITY><ZIP>SW1Y 4QX</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT><CREATORS MODIFIED="2018-01-17 14:06:11 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="59249928586857976988110908155847" ROLE="AUTHOR"><FIRST_NAME>Hanna</FIRST_NAME><LAST_NAME>Bergman</LAST_NAME><EMAIL_1>hbergman@cochrane.org</EMAIL_1><EMAIL_2>behanna@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Cochrane Response</DEPARTMENT><ORGANISATION>Cochrane</ORGANISATION><ADDRESS_1>St Albans House</ADDRESS_1><ADDRESS_2>57-59 Haymarket</ADDRESS_2><CITY>London</CITY><ZIP>SW1Y 4QX</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="12341" ROLE="AUTHOR"><FIRST_NAME>Karla</FIRST_NAME><LAST_NAME>Soares-Weiser</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Deputy Editor in Chief</POSITION><EMAIL_1>ksoares-weiser@cochrane.org</EMAIL_1><EMAIL_2>ksoaresweiser@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Cochrane Editorial Unit</DEPARTMENT><ORGANISATION>Cochrane</ORGANISATION><ADDRESS_1>St Albans House, 57 - 59 Haymarket</ADDRESS_1><CITY>London</CITY><ZIP>SW1Y 4QX</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>02071837503</PHONE_1></ADDRESS></PERSON></CREATORS><DATES MODIFIED="2017-10-04 13:10:12 +0100" MODIFIED_BY="[Empty name]"><UP_TO_DATE><DATE DAY="26" MONTH="4" YEAR="2017"/></UP_TO_DATE><LAST_SEARCH><DATE DAY="26" MONTH="4" YEAR="2017"/></LAST_SEARCH><NEXT_STAGE><DATE DAY="12" MONTH="10" YEAR="2019"/></NEXT_STAGE><PROTOCOL_PUBLISHED ISSUE="2" YEAR="1996"/><REVIEW_PUBLISHED ISSUE="3" YEAR="1997"/><LAST_CITATION_ISSUE ISSUE="1" YEAR="2018"/></DATES><WHATS_NEW MODIFIED="2017-12-19 13:17:08 +0000" MODIFIED_BY="[Empty name]"><WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-10-04 13:08:06 +0100" MODIFIED_BY="[Empty name]"><DATE DAY="4" MONTH="10" YEAR="2017"/><DESCRIPTION><P>Results from latest searches have not altered the conclusions of this review.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-12-19 13:17:08 +0000" MODIFIED_BY="[Empty name]"><DATE DAY="26" MONTH="4" YEAR="2017"/><DESCRIPTION><P>Update search run 26 April 2017. Eight records found and assessed by Cochrane Schizophrenia editorial base, no new studies relevant to this review found. The 8 records added to Miscellaneous Treatments this series of Tardive Dyskinesia reviews; (see also <LINK TAG="SEARCH_RESULTS" TYPE="SECTION">Results of the search</LINK>)</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><DATE DAY="18" MONTH="11" YEAR="2016"/><DESCRIPTION><P>Title changed from 'Anticholinergic medication for neuroleptic-induced tardive dyskinesia'. Two new included trials added (<LINK REF="STD-Bucci-1971" TYPE="STUDY">Bucci 1971</LINK>; <LINK REF="STD-Greil-1984" TYPE="STUDY">Greil 1984</LINK>), analyses and text updated, outcomes list updated due to patient consultation, 'Summary of findings' table added, conclusions not substantially changed.</P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW><HISTORY MODIFIED="2017-10-04 14:26:33 +0100" MODIFIED_BY="[Empty name]"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-10-04 14:26:33 +0100" MODIFIED_BY="[Empty name]"><DATE DAY="16" MONTH="7" YEAR="2015"/><DESCRIPTION><P>Update search run July 15 2015. 704 records found and assessed by review authors.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-11-18 11:44:25 +0000" MODIFIED_BY="[Empty name]"><DATE DAY="11" MONTH="11" YEAR="2013"/><DESCRIPTION><P>Search was updated and 58 possibly related references were sent to the author.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-11-18 11:44:03 +0000" MODIFIED_BY="[Empty name]"><DATE DAY="6" MONTH="8" YEAR="2012"/><DESCRIPTION><P>Update search of Cochrane Schizophrenia Group's Trial Register (see <A HREF="http://archie.cochrane.org/sections/documents/view?version=44705070754671417758120516110605&amp;format=REVMAN#SEARCH_METHODS">Search methods for identification of studies</A>), 8 studies added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-11-18 11:43:57 +0000" MODIFIED_BY="[Empty name]"><DATE DAY="4" MONTH="8" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-08-04 14:59:08 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="14" MONTH="4" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-14 14:15:55 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="25" MONTH="4" YEAR="2008"/><DESCRIPTION><P>Converted to new review format.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS"><DATE DAY="14" MONTH="2" YEAR="1997"/><DESCRIPTION><P>Substantive amendment</P></DESCRIPTION></WHATS_NEW_ENTRY></HISTORY><SOURCES_OF_SUPPORT MODIFIED="2016-10-19 08:05:07 +0100" MODIFIED_BY="[Empty name]"><INTERNAL_SOURCES MODIFIED="2016-10-19 08:05:07 +0100" MODIFIED_BY="[Empty name]"><SOURCE><NAME>CAPES - Ministry of Education</NAME><COUNTRY CODE="BR">Brazil</COUNTRY><DESCRIPTION/></SOURCE><SOURCE><NAME>Queensland Health</NAME><COUNTRY CODE="AU">Australia</COUNTRY><DESCRIPTION/></SOURCE><SOURCE><NAME>Universidade Federal de Sao Paulo</NAME><COUNTRY CODE="BR">Brazil</COUNTRY><DESCRIPTION/></SOURCE><SOURCE MODIFIED="2016-10-19 08:05:07 +0100" MODIFIED_BY="[Empty name]"><NAME>Enhance Reviews Ltd.</NAME><COUNTRY CODE="GB">UK</COUNTRY><DESCRIPTION><P>Logistics support for Hanna Bergman</P></DESCRIPTION></SOURCE></INTERNAL_SOURCES><EXTERNAL_SOURCES MODIFIED="2016-10-19 08:04:29 +0100" MODIFIED_BY="[Empty name]"><SOURCE MODIFIED="2016-10-19 08:04:29 +0100" MODIFIED_BY="[Empty name]"><NAME>NIHR HTA Project Grant, reference number: 14/27/02</NAME><COUNTRY CODE="GB">UK</COUNTRY><DESCRIPTION><P>Salary support for Hanna Bergman.<BR/>Support for patient involvement consultation.<BR/>Support for traceable data database.</P></DESCRIPTION></SOURCE></EXTERNAL_SOURCES></SOURCES_OF_SUPPORT><MESH_TERMS VERIFIED="NO"/><KEYWORDS/></COVER_SHEET><MAIN_TEXT MODIFIED="2018-01-17 14:04:59 +0000" MODIFIED_BY="[Empty name]"><SUMMARY MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><TITLE MODIFIED="2017-12-19 13:08:50 +0000" MODIFIED_BY="[Empty name]">Anticholinergic medication for people who have tardive dyskinesia after taking antipsychotic medication</TITLE><SUMMARY_BODY MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P><B>Review question</B>.</P><P>Are anticholinergic drugs or withdrawal of anticholinergic drugs effective in the treatment of tardive dyskinesia in people with schizophrenia or other similar mental health problems.</P><P><B>Background</B>.</P><P>People with schizophrenia often hear voices and see things (hallucinations) and have beliefs which are at odds with those held by people without schizophrenia (delusions). The main treatment of these symptoms are antipsychotic drugs. However, these drugs can have debilitating side-effects. Tardive dyskinesia is an involuntary movement that causes the face, mouth, tongue and jaw to convulse, spasm and grimace. It is caused by long-term use, or high doses, of antipsychotic drugs, is difficult to treat and can be incurable. Many people being treated with antipsychotic medication also receive anticholinergic drugs to try to reduce some of these movement side-effects. There is, however, evidence from animal experiments that anticholinergic drugs could cause tardive dyskinesia.</P><P><B>Study characteristics</B>.</P><P>The review includes two small randomised studies with a total of 30 people with schizophrenia who had also developed antipsychotic-induced tardive dyskinesia. Participants in one study received either the anticholinergic drug procyclidine or isocarboxacid, an antidepressant drug. One participant group in the other study was withdrawn from the anticholinergic drug biperiden whereas the other group of participants continued taking biperiden.</P><P><B>Key results</B>.</P><P>There were sparse findings from two small and poorly reported trials. It is uncertain whether giving anticholinergic drugs is helpful in the treatment of tardive dyskinesia for people who are taking antipsychotic medication. It is also uncertain whether the withdrawal of anticholinergic medication improves the symptoms of tardive dyskinesia.</P><P><B>Quality of the evidence</B>.</P><P>Available evidence is very low or low quality, limited, and small scale. It is not possible to recommend these drugs or the withdrawal of these drugs as a treatment for tardive dyskinesia. To fully investigate whether the withdrawal of anticholinergic drugs has any positive effects for people with tardive dyskinesia, we need more high quality research data.</P><P>This plain language summary was adapted by the review authors from a summary originally written by Ben Gray, Senior Peer Researcher, McPin Foundation (<A HREF="http://mcpin.org/">mcpin.org</A>).</P></SUMMARY_BODY></SUMMARY><ABSTRACT MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><ABS_BACKGROUND MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Antipsychotic (neuroleptic) medication is used extensively to treat people with serious mental illnesses. However, it is associated with a wide range of adverse effects, including movement disorders. Because of this, many people treated with antipsychotic medication also receive anticholinergic drugs in order to reduce some of the associated movement side-effects. However, there is also a suggestion from animal experiments that the chronic administration of anticholinergics could cause tardive dyskinesia.</P></ABS_BACKGROUND><ABS_OBJECTIVES MODIFIED="2017-12-19 13:08:50 +0000" MODIFIED_BY="[Empty name]"><P>To determine whether the use or the withdrawal of anticholinergic drugs (benzhexol, benztropine, biperiden, orphenadrine, procyclidine, scopolamine, or trihexylphenidyl) are clinically effective for the treatment of people with both antipsychotic-induced tardive dyskinesia and schizophrenia or other chronic mental illnesses.</P></ABS_OBJECTIVES><ABS_SEARCH_STRATEGY MODIFIED="2017-10-17 12:55:48 +0100" MODIFIED_BY="[Empty name]"><P>We retrieved 712 references from searching the Cochrane Schizophrenia Group's Study-Based Register of Trials including the registries of clinical trials (16 July 2015 and 26 April 2017). We also inspected references of all identified studies for further trials and contacted authors of trials for additional information.</P></ABS_SEARCH_STRATEGY><ABS_SELECTION_CRITERIA MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>We included reports identified in the search if they were controlled trials dealing with people with antipsychotic-induced tardive dyskinesia and schizophrenia or other chronic mental illness who had been randomly allocated to (a) anticholinergic medication versus placebo (or no intervention), (b) anticholinergic medication versus any other intervention for the treatment of tardive dyskinesia, or (c) withdrawal of anticholinergic medication versus continuation of anticholinergic medication.</P></ABS_SELECTION_CRITERIA><ABS_DATA_COLLECTION MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>We independently extracted data from included trials and we estimated risk ratios (RR) with 95% confidence intervals (CIs). We assumed that people who left early had no improvement. We assessed risk of bias and created a 'Summary of findings' table using GRADE.</P></ABS_DATA_COLLECTION><ABS_RESULTS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>The previous version of this review included no trials. We identified two trials that could be included from the 2015 and 2017 searches. They randomised 30 in- and outpatients with schizophrenia in the USA and Germany. Overall, the risk of bias was unclear, mainly due to poor reporting: allocation concealment was not described; generation of the sequence was not explicit; studies were not clearly blinded; and outcome data were not fully reported.</P><P>Findings were sparse. One study reported on the primary outcomes and found that significantly more participants allocated to procyclidine (anticholinergic) had not improved to a clinically important extent compared with those allocated to isocarboxazid (MAO-inhibitor) after 40 weeks' treatment (1 RCT, n = 20; RR 4.20, 95% CI 1.40 to 12.58; <I>very</I> <I>low quality evidence</I>); that there was no evidence of a difference in the incidence of any adverse effects (1 RCT, n = 20; RR 0.33, 95% CI 0.02 to 7.32; <I>very low quality evidence</I>); or acceptability of treatment (measured by participants leaving the study early) (1 RCT, n = 20; RR 0.33, 95% CI 0.02 to 7.32; <I>very low quality evidence</I>). The other trial compared anticholinergic withdrawal with anticholinergic continuation and found no evidence of a difference in the incidence of acceptability of treatment (measured by participants leaving the study early) (1 RCT, n = 10; RR 2.14, 95% CI 0.11 to 42.52; <I>very low quality evidence</I>).</P><P>No trials reported on social confidence, social inclusion, social networks, or personalised quality of life &#8212; outcomes designated important to patients. No studies comparing either i. anticholinergics with placebo or no treatment, or ii. studies of anticholinergic withdrawal, were found that reported on the primary outcome 'no clinically important improvement in TD symptoms and adverse events'.</P></ABS_RESULTS><ABS_CONCLUSIONS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Based on currently available evidence, no confident statement can be made about the effectiveness of anticholinergics to treat people with antipsychotic-induced tardive dyskinesia. The same applies for the withdrawal of such medications. Whether the withdrawal of anticholinergics may benefit people with antipsychotic-induced TD should be evaluated in a parallel-group, placebo-controlled randomised trial, with adequate sample size and at least 6 weeks of follow-up.<BR/></P></ABS_CONCLUSIONS></ABSTRACT><BODY MODIFIED="2018-01-17 13:58:36 +0000" MODIFIED_BY="[Empty name]"><BACKGROUND MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><CONDITION MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Since the 1950s antipsychotic (neuroleptic) medication has been used extensively to treat people with chronic mental illnesses, such as schizophrenia. These drugs can effectively control symptoms such as abnormal perceptions (hallucinations), disordered thinking and fixed false beliefs (delusions). In addition, maintenance therapy with antipsychotics is associated with a reduced risk of relapses (<LINK REF="REF-Schooler-1993" TYPE="REFERENCE">Schooler 1993</LINK>). However, antipsychotic medication has also been associated with a wide range of adverse effects, including movement disorders. The appearance of these disorders can be extremely disfiguring, compounds stigma, and is associated with poor compliance to antipsychotic treatment (<LINK REF="REF-Barnes-1993" TYPE="REFERENCE">Barnes 1993</LINK>; <LINK REF="REF-Tarsy-2011" TYPE="REFERENCE">Tarsy 2011</LINK>).</P><P>Tardive dyskinesia (TD) is one such movement disorder and is characterised by abnormal, repetitive and involuntary movements. TD is a chronic condition of insidious onset, the severity of which spontaneously fluctuates (<LINK REF="REF-APA-1992" TYPE="REFERENCE">APA 1992</LINK>). The clinical features include tongue protrusion, side-to-side or rotatory movement of the jaw, lip smacking, puckering and pursing, and rapid eye blinking (<LINK REF="REF-Casey-1994" TYPE="REFERENCE">Casey 1994</LINK>). In some people rapid movements of the arms, legs, and trunk may also occur. Studies on the natural history of TD have reported widely variable remission rates (1% to 62%) depending on patient age, psychiatric diagnosis, course of the psychiatric disorder, and duration of therapy (<LINK REF="REF-Bergen-1989" TYPE="REFERENCE">Bergen 1989</LINK>; <LINK REF="REF-Fernandez-2001" TYPE="REFERENCE">Fernandez 2001</LINK>; <LINK REF="REF-Glazer-1990" TYPE="REFERENCE">Glazer 1990</LINK>). It occurs in more than 20% of those using antipsychotic medication continually for longer than three months. Every year 4% to 5% of adults and 25% to 30% of elderly persons who continually use these drugs begin to show signs of TD (<LINK REF="REF-APA-1992" TYPE="REFERENCE">APA 1992</LINK>; <LINK REF="REF-Correll-2004" TYPE="REFERENCE">Correll 2004</LINK>). This disorder can result in considerable social and physical disability (<LINK REF="REF-Barnes-1993" TYPE="REFERENCE">Barnes 1993</LINK>).</P><P>The prevalence of TD is often thought to be decreasing based on the use of second generation antipsychotics (SGA) in place of first generation antipsychotics (FGA) (<LINK REF="REF-Cloud-2014" TYPE="REFERENCE">Cloud 2014</LINK>). A systematic review found that the incidence of TD associated with SGAs (2% to 4%) was significantly lower than that for FGAs (5% to 8%) (<LINK REF="REF-Correll-2008" TYPE="REFERENCE">Correll 2008</LINK>). Despite this, widespread use of SGAs in clinical settings may still result in an overall increase in the number of cases of TD (<LINK REF="REF-Glazer-2000" TYPE="REFERENCE">Glazer 2000</LINK>).</P><P>Although the most frequent cause of TD is the use of antipsychotic medication it is striking that dose reduction can lead to a temporary exacerbation in symptoms. Conversely, increasing the dose is often associated with a temporary remission (<LINK REF="REF-Cavallaro-1993" TYPE="REFERENCE">Cavallaro 1993</LINK>; <LINK REF="REF-Smith-1980" TYPE="REFERENCE">Smith 1980</LINK>). Antipsychotic drugs block certain chemical receptor sites in the brain &#8212; one of these is specific for dopamine (<LINK REF="REF-Casey-1994" TYPE="REFERENCE">Casey 1994</LINK>). One hypothesis explaining the cause of antipsychotic-induced TD is that chronic blockade of dopamine receptors in specific cells of the brain (neurones from the nigrostriatum) causes an overgrowth of these receptors (<LINK REF="REF-Casey-1994" TYPE="REFERENCE">Casey 1994</LINK>). Consequently, interactions between antipsychotic drugs and dopamine receptors in the brain have been proposed as both the mechanisms for their beneficial effects in psychoses as well as the cause of the movement disorder side effects, including TD (<LINK REF="REF-Jeste-1982" TYPE="REFERENCE">Jeste 1982</LINK>). In addition, there is evidence to suggest that an imbalance between cells that use dopamine and cells that use acetylcholine may be a cause of TD (<LINK REF="REF-Alphs-1983" TYPE="REFERENCE">Alphs 1983</LINK>, <LINK REF="REF-Casey-1994" TYPE="REFERENCE">Casey 1994</LINK>).</P></CONDITION><INTERVENTION MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Drugs that reduce the activity of the cholinergic cells (anticholinergic drugs) are widely used to help treat other antipsychotic-induced movement disorders such as parkinsonism and dystonia (<LINK REF="REF-APA-1992" TYPE="REFERENCE">APA 1992</LINK>). Many acutely psychotic patients who receive antipsychotic medication also receive anticholinergic drugs in order to reduce some of the movement side effects associated with antipsychotic medication. However, anticholinergic drugs can cause many undesirable side effects, such as dryness of mouth, constipation, blurring of vision, and confusion (<LINK REF="REF-APA-1992" TYPE="REFERENCE">APA 1992</LINK>).</P></INTERVENTION><THEORY MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>The rationale for the use of anticholinergic drugs in TD is less clear, as there is a suggestion from animal experiments that the chronic administration of anticholinergics could increase the supersensitivity of dopamine receptors and consequently cause TD (<LINK REF="REF-Kane-1994" TYPE="REFERENCE">Kane 1994</LINK>). As a result these drugs have not been widely used for the treatment of antipsychotic-induced TD.</P></THEORY><IMPORTANCE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Several SGAs have been produced in the last decades that are claimed to cause less or no TD (<LINK REF="REF-Lieberman-1996" TYPE="REFERENCE">Lieberman 1996</LINK>). These claims may or may not be true: certainly evidence does indicate that thoughtful use of older generation drugs is not associated with more TD than occurs with newer treatments (<LINK REF="REF-Chouinard-2008" TYPE="REFERENCE">Chouinard 2008</LINK>). Furthermore it is likely that the less expensive and more familiar drugs &#8212; such as chlorpromazine or haloperidol &#8212; will continue to be the mainstay of treatment of people with schizophrenia in a global context (<A HREF="http://www.who.int/medicines/publications/essentialmedicines/Updated_sixteenth_adult_list_en.pdf">WHO Essential List 2010</A>). Use of drugs such as these is associated with emergence of TD and therefore this condition will remain a problem for years to come.</P><P>Given the high incidence and prevalence of TD among people taking antipsychotic medication, the need for prevention or treatment is clear. Unfortunately, there has been sparse evidence to guide clinicians (<LINK REF="REF-NICE-2014" TYPE="REFERENCE">NICE 2014</LINK>; <LINK REF="REF-Taylor-2009" TYPE="REFERENCE">Taylor 2009</LINK>). Although many treatments have been tested, no one intervention has been shown clearly to be effective. Cessation or reduction of the dose of antipsychotic medication is the ideal management for TD. In clinical practice this is not always possible, not least because in many individuals such a reduction would lead to relapse. This review focuses on whether the addition or withdrawal of anticholinergic drugs to those already receiving antipsychotic medication is likely to help TD.</P><P>This review is one in a series of Cochrane Reviews (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) evaluating treatments for antipsychotic-induced TD, and is an update of a Cochrane Review first published in 1997 (<LINK REF="REF-Soares_x002d_Weiser-1997" TYPE="REFERENCE">Soares-Weiser 1997</LINK>).</P></IMPORTANCE></BACKGROUND><OBJECTIVES MODIFIED="2017-12-18 16:01:05 +0000" MODIFIED_BY="[Empty name]"><P>To determine whether the use or the withdrawal of anticholinergic drugs (benzhexol, benztropine, biperiden, orphenadrine, procyclidine, scopolamine, or trihexyphenidyl) are clinically effective for the treatment of people with both antipsychotic-induced tardive dyskinesia and schizophrenia or other chronic mental illnesses.</P></OBJECTIVES><METHODS MODIFIED="2018-01-17 13:58:36 +0000" MODIFIED_BY="[Empty name]"><SELECTION_CRITERIA MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><CRIT_STUDIES MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>All relevant randomised controlled trials. Where a trial was described as 'double-blind' but it implied that the study was randomised and the demographic details of each group were similar, we included it. We had planned to exclude quasi-randomised studies, such as those allocated by using alternate days of the week (see <LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK>).</P></CRIT_STUDIES><CRIT_PARTICIPANTS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Adults, however defined, with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder, by any means of diagnosis. We are interested in making sure that information is as relevant as possible to the current care of people with schizophrenia, so if information was available we highlighted the current clinical state of participants (acute, early post-acute, partial remission, remission), the stage (prodromal, first episode, early illness, persistent) and whether the studies primarily focused on people with particular problems (for example negative symptoms, treatment-resistant illnesses).</P></CRIT_PARTICIPANTS><CRIT_INTERVENTIONS MODIFIED="2017-12-18 16:01:37 +0000" MODIFIED_BY="[Empty name]"><P>i. Anticholinergic drugs (benzhexol, benztropine, biperiden, dexetimide, orphenadrine, procyclidine, scopolamine, trihexyphenidyl) compared to placebo, or no intervention;<BR/>ii. anticholinergic drugs (as above) compared to any other intervention to treat TD; or<BR/>iii. the withdrawal of the above anticholinergic drugs compared with the continuation of the treatment.</P></CRIT_INTERVENTIONS><CRIT_OUTCOMES MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>We have defined clinical efficacy as an improvement in the symptoms of TD of more than 50%, on any scale. We grouped outcomes into short term (less than 6 weeks), medium term (between 6 weeks and six months) and long term (more than six months).</P><CRIT_OUTCOMES_PRIMARY MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="5">1. Tardive dyskinesia</HEADING><P>No clinically important improvement in the symptoms of individuals, defined as more than 50% improvement on any TD scale &#8210; any time period.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2. Adverse effects</HEADING><P>No clinically significant extrapyramidal adverse effects &#8210; any time period.</P></SUBSECTION></CRIT_OUTCOMES_PRIMARY><CRIT_OUTCOMES_SECONDARY MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="5">1. Tardive dyskinesia (TD)</HEADING><P>1.1 Any improvement in the symptoms of individuals on any TD scale, as opposed to no improvement.<BR/>1.2 Deterioration in the symptoms of individuals, defined as any deleterious change on any TD scale.<BR/>1.3 Average change in severity of TD during the trial period.<BR/>1.4 Average difference in severity of TD at the end of the trial.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2. General mental state changes</HEADING><P>2.1 Deterioration in general psychiatric symptoms (such as delusions and hallucinations) defined as any deleterious change on any scale.<BR/>2.2 Average difference in severity of psychiatric symptoms at the end of the trial.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">3. Acceptability of the treatment</HEADING><P>3.1 Acceptability of the intervention to the participant group as measured by numbers of people dropping out during the trial.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">4. Adverse effects</HEADING><P>4.1 Use of any anti-parkinsonism drugs.<BR/>4.2 Average score/change in extrapyramidal adverse effects.<BR/>4.3 Acute dystonia.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">5. Other adverse effects, general and specific</HEADING></SUBSECTION><SUBSECTION><HEADING LEVEL="5">6. Hospital and service utilisation outcomes</HEADING><P>6.1 Hospital admission.<BR/>6.2 Average change in days in hospital.<BR/>6.3 Improvement in hospital status (for example: change from formal to informal admission status, use of seclusion, level of observation).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">7. Economic outcomes</HEADING><P>7.1 Average change in total cost of medical and mental health care.<BR/>7.2 Total indirect and direct costs.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">8. Social confidence, social inclusion, social networks, or personalised quality of life measures</HEADING><P>8.1. No significant change in social confidence, social inclusion, social networks, or personalised quality of life measures.<BR/>8.2 Average score/change in social confidence, social inclusion, social networks, or personalised quality of life measures.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">9. Behaviour</HEADING><P>9.1 Clinically significant agitation.<BR/>9.2 Use of adjunctive medication for sedation.<BR/>9.3 Aggression to self or others.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">10. Cognitive state</HEADING><P>10.1 No clinically important change.<BR/>10.2 No change, general and specific.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">'Summary of findings' table</HEADING><P>We used the GRADE approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>); and <A HREF="http://www.tech.cochrane.org/gradepro">GRADEPRO</A> to import data from <A HREF="http://www.tech.cochrane.org/revman">Review Manager</A> to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of the available data on all outcomes we rated as important to patient care and decision making. This summary was used to guide our conclusions and recommendations. We selected the following main outcomes for inclusion in the 'Summary of findings' table.</P><SUBSECTION><HEADING LEVEL="5">1. Tardive dyskinesia</HEADING><P>1.1 Improved to a clinically important extent.<BR/>1.2 Deteriorated.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2. Mental state</HEADING><P>2.1 Deterioration.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">3. Adverse effects</HEADING><P>3.1 Any adverse event.<BR/>3.2 Adverse effects: no clinically significant extrapyramidal adverse effects.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">4. Acceptability of treatment</HEADING><P>4.1 Leaving the study early.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">5. Social confidence, social inclusion, social networks, or personalised quality-of-life measures*</HEADING><P>5.1 No significant change in social confidence, social inclusion, social networks, or personalised quality of life measures for either recipients of care or caregivers.<BR/></P><P>* Outcome designated important to patients. We wished to add perspectives from people&#8217;s personal experience with TD to the research agenda. A consultation with service users was planned where a previously published version of a review in the Cochrane TD series and a lay overview of that review gave the foundation for the discussions (<LINK REF="REF-Soares_x002d_Weiser-2011" TYPE="REFERENCE">Soares-Weiser 2011</LINK>; <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The session was planned to provide time to reflect on current research on TD and consider gaps in knowledge. The report is not completed but we will add a link to it within this review. In the meantime we have added one figure showing a service user's feelings concerning this neglected area of research (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Informed by the results of the consultation, for this review we included outcomes important to service users to the 'Summary of findings' table.</P></SUBSECTION></SUBSECTION></CRIT_OUTCOMES_SECONDARY></CRIT_OUTCOMES></SELECTION_CRITERIA><SEARCH_METHODS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><ELECTRONIC_SEARCHES MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>The 2017 review update was carried out in parallel with updating eight other TD reviews: see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for details. The search covered all nine TD reviews.</P><SUBSECTION><HEADING LEVEL="4">Cochrane Schizophrenia Group's Study-Based Register of Trials</HEADING><P>On 16 July 2015 and 26 April 2017, the Information Specialist searched the register using the following search strategy:</P><P>*Tardive Dyskinesia* in Health Care Condition Field of STUDY</P><P>In such study-based registers, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics (<LINK REF="REF-Shokraneh-2017" TYPE="REFERENCE">Shokraneh 2017</LINK>).</P><P>This register is compiled by systematic searches of major resources (AMED, BIOSIS, CINAHL, ClinicalTrials.gov, Embase, MEDLINE, PsycINFO, PubMed, WHO ICTRP) and their monthly updates; ProQuest Dissertations and Theses A&amp;I and its quarterly update; Chinese databases (CBM, CNKI, and Wanfang) and their annual updates; handsearches; grey literature; and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group's Module</A>). There are no language, date, document type, or publication status limitations for inclusion of records into the register.</P><P>For previous searches, please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P></SUBSECTION></ELECTRONIC_SEARCHES><OTHER_SEARCHES MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="4">1. Reference searching</HEADING><P>We inspected references of all included studies for further relevant studies.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2. Personal contact</HEADING><P>Where necessary, we contacted the first author of each included study for information regarding unpublished trials. We noted the outcome of this contact in the <LINK TAG="INCLUDED_STUDIES" TYPE="SECTION">Included studies</LINK> or <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> tables.</P></SUBSECTION></OTHER_SEARCHES></SEARCH_METHODS><DATA_COLLECTION MODIFIED="2018-01-17 13:58:36 +0000" MODIFIED_BY="[Empty name]"><STUDY_SELECTION MODIFIED="2018-01-17 13:58:36 +0000" MODIFIED_BY="[Empty name]"><P>For the 2017 update, reviewers RA and AG (see <LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK>) inspected all abstracts of studies identified as above for potentially relevant reports. We resolved disagreement by discussion; or, where there was still doubt, we acquired the full article for further inspection. We acquired the full articles of relevant reports/abstracts meeting initial criteria for reassessment and carefully inspected for a final decision on inclusion (see <LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK>). RA and AG were not blinded to the names of the authors, institutions or journal of publication. Where difficulties or disputes arose, we asked author HB for help; and where it was impossible to decide or if adequate information was not available to make a decision, we added these studies to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> and contacted the authors of the papers for clarification.</P></STUDY_SELECTION><DATA_EXTRACTION MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="4">1. Extraction</HEADING><P>For the 2017 update, reviewers RA and HB independently extracted data from all included studies. Again, we discussed any disagreement and documented decisions. KSW helped clarify issues with any remaining problems and we documented these final decisions. We extracted data presented only in graphs and figures whenever possible, but included them only if two reviewers independently had the same result. We attempted to contact authors through an open-ended request in order to obtain missing information or for clarification whenever necessary. If studies were multi-centre, where possible we extracted data relevant to each component centre separately.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2. Management</HEADING><SUBSECTION><HEADING LEVEL="5">2.1 Forms</HEADING><P>For the 2017 update we extracted data to simple forms. Extracted data are available <A HREF="https://www.researchgate.net/publication/308698005_Appendix_Traceable_Extracted_Data_from_Included_Studies_of_Tardive_Dyskinesia_Reviews?channel=doi&amp;linkId=57ebe1c508ae92a5dbd051c1&amp;showFulltext=true">here</A> with a link to the original source PDF for each item.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2.2 Scale-derived data</HEADING><P>We included continuous data from rating scales only if:</P><P>a) the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>);<BR/>b) the measuring instrument has not been written or modified by one of the trialists for that particular trial; and<BR/>c) the instrument should be a global assessment of an area of functioning and not sub-scores which are not, in themselves, validated or shown to be reliable. However there are exceptions, we included sub-scores from mental state scales measuring positive and negative symptoms of schizophrenia.<BR/><BR/>Ideally the measuring instrument should either be i. a self-report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we noted in <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK> if this was the case or not.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2.3 Endpoint versus change data</HEADING><P>There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult-to-measure conditions such as schizophrenia. We decided to primarily use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we preferred to use mean differences (MD) rather than standardised mean differences throughout (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2.4 Skewed data</HEADING><P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we applied the following standards to relevant data before inclusion; see (a) and (b) below.<BR/></P><P>Please note: we would have entered data from studies of at least 200 participants in the analysis, because skewed data pose less of a problem in large studies. We also would have entered all relevant change data as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not.</P><P>For endpoint data from studies of fewer than 200 participants:</P><P>(a) when a scale starts from the &#64257;nite number zero, we planned to subtract the lowest possible value from the mean, and divide this by the standard deviation. If this value was lower than 1, it strongly suggests a skew and we would have excluded these data. If this ratio was higher than 1 but below 2, there is suggestion of skew. We would have entered these data and tested whether its inclusion or exclusion changed the results substantially. Finally, if the ratio was larger than 2 we would have included these data, because skew is less likely (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P><P>(b) if a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>)) which can have values from 30 to 210), we would have modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S &#8722; S min), where S is the mean score and 'S min' is the minimum score.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2.5 Common measure</HEADING><P>Where relevant, to facilitate comparison between trials we would have converted variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2.6 Conversion of continuous to binary</HEADING><P>Where possible, we converted continuous outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this can be considered as a clinically significant response (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>, <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2.7 Direction of graphs</HEADING><P>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for anticholinergic medication. Where keeping to this made it impossible to avoid outcome titles with clumsy double-negatives (e.g. 'Not un-improved') we presented data where the left of the line indicates an unfavourable outcome and noted this in the relevant graphs.</P></SUBSECTION></SUBSECTION></DATA_EXTRACTION><QUALITY_ASSESSMENT MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Reviewers RA and HB independently assessed risk of bias within the included studies by using criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>to assess trial quality (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.</P><P>If the raters disagreed, we made the final rating by consensus, with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain further information. If non-concurrence occurred, we reported this.</P><P>We noted the level of risk of bias in the text of the review and in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK> and <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>.</P></QUALITY_ASSESSMENT><EFFECT_MEASURES MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="4">1. Binary data</HEADING><P>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive than odds ratios (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>), as odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2. Continuous data</HEADING><P>For continuous outcomes we estimated mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we presumed there is a small difference in measurement, and calculated effect size and transformed the effect back to the units of one or more of the specific instruments.</P></SUBSECTION></EFFECT_MEASURES><UNIT_OF_ANALYSIS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="4">1. Cluster trials</HEADING><P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data can be a problem. Authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>), whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P><P>If any of the included trials had randomised participants by clusters, and where clustering is not accounted for in primary studies, we would have presented such data in a table, with a (*) symbol to indicate the presence of a probable 'unit of analysis' error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation coefficients for their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will present these data as if from a non-cluster randomised study, but adjust for the clustering effect.</P><P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra-class correlation coefficient (ICC) (Design effect = 1 + (m &#8722; 1) * ICC) (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC is not reported it will be assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P><P>If cluster studies have been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse variance technique.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2. Cross-over trials</HEADING><P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systemically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross-over studies.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING><P>Where a study involves more than two treatment arms, if relevant we presented the additional treatment arms in comparisons. If data were binary we simply added and combined within the two-by-two table. If data were continuous we combined data following the formula in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>)<I>.</I> We did not use data where the additional treatment arms were not relevant.</P></SUBSECTION></UNIT_OF_ANALYSIS><MISSING_DATA MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="4">1. Overall loss of credibility</HEADING><P>At some degree of loss to follow-up, data must lose credibility (<LINK REF="REF-Xia-2009" TYPE="REFERENCE">Xia 2009</LINK>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we addressed this within the 'Summary of findings' table/s by down-rating quality. We also downgraded quality within the 'Summary of findings' table/s should loss be 25% to 50% in total.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2. Binary</HEADING><P>In the case where attrition for a binary outcome is between 0% and 50% and where these data are not clearly described, we presented data on a 'once-randomised-always-analyse' basis (an 'intention to treat' analysis). We assumed all those leaving the study early had no improvement. We undertook a sensitivity analysis testing how prone the primary outcomes were to change by comparing data only from people who completed the study to that point to the 'intention to treat' analysis using the above assumptions.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">3. Continuous</HEADING><SUBSECTION><HEADING LEVEL="5">3.1 Attrition</HEADING><P>We reported and used data where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">3.2 Standard deviations</HEADING><P>If standard deviations were not reported, we first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data but an exact standard error and confidence intervals available for group means, and either P value or t value available for differences in mean, we calculated them according to the rules described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>): when only the standard error (SE) is reported, standard deviations (SDs) are calculated by the formula SD = SE * &#8730;(n). Chapters 7.7.3 and 16.1.3 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> present detailed formulae for estimating SDs from P, t or F values, confidence intervals, ranges or other statistics (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If these formulae did not apply, we calculated the SDs according to a validated imputation method which is based on the SDs of the other included studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study&#8217;s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">3.3 Assumptions about participants who left the trials early or were lost to follow-up</HEADING><P>Various methods are available to account for participants who left the trials early or were lost to follow-up. Some trials just present the results of study completers, others use the method of last observation carried forward (LOCF), while more recently methods such as multiple imputation or mixed-effects models for repeated measurements (MMRM) have become more of a standard. While the last two methods seem to be somewhat better than LOCF (<LINK REF="REF-Leon-2006" TYPE="REFERENCE">Leon 2006</LINK>), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia trials. We therefore did not exclude studies based on which statistical approach had been used. However, we preferred to use the more sophisticated approaches (e.g. MMRM or 'multiple-imputation') and only presented completer analyses if some kind of ITT data were not available at all. Moreover, we addressed this issue in the item 'Incomplete outcome data' of the 'Risk of bias' tool.</P></SUBSECTION></SUBSECTION></MISSING_DATA><HETEROGENEITY_ASSESSMENT MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="4">1. Clinical heterogeneity</HEADING><P>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise and discussed in the text if they arose.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2. Methodological heterogeneity</HEADING><P>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise and discussed in the text if they arose.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">3. Statistical heterogeneity</HEADING><SUBSECTION><HEADING LEVEL="5">3.1 Visual inspection</HEADING><P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">3.2 Employing the I² statistic</HEADING><P>We investigated heterogeneity between studies by considering the I² method alongside the Chi² P value. The I² provides an estimate of the percentage of inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of I² depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from Chi²  test, or a confidence interval for I²). An I² estimate equal to or greater than around 50% accompanied by a statistically significant Chi² statistic can be interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 <I>Cochrane Handbook for Systematic Reviews of Interventions; </I><LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We explored and discussed in the text potential reasons for substantial levels of heterogeneity (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P></SUBSECTION></SUBSECTION></HETEROGENEITY_ASSESSMENT><BIAS_ASSESSMENT MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in Section 10 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We would not have used funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In future versions of this review, if funnel plots are possible we will seek statistical advice in their interpretation.</P></BIAS_ASSESSMENT><DATA_SYNTHESIS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>We understand that there is no closed argument for preference of fixed-effect models over random-effects models, or vice versa. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random-effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose the fixed-effect model for all analyses.</P></DATA_SYNTHESIS><SUBGROUP_ANALYSIS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="4">1. Subgroup analyses</HEADING><SUBSECTION><HEADING LEVEL="5">1.1 Primary outcomes</HEADING><P>We anticipated one sub-group analysis to test the hypothesis that the modification of anticholinergic medication is most effective for those with early onset TD (less than five years). We had hoped to present data for this subgroup for the primary outcomes.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">1.2 Clinical state, stage or problem</HEADING><P>We proposed to undertake this review and provide an overview of the effects of anticholinergic medication for people with schizophrenia in general. In addition, however, we had wanted to report data on subgroups of people in the same clinical state, stage and with similar problems.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2. Investigation of heterogeneity</HEADING><P>We would have reported when inconsistency was high. First we would have investigated whether data were entered correctly. Second, if data were correct, we would have visually inspected the graph and successively removed studies from the company of the rest to see if homogeneity was restored. For this review we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present data. If not, we would not pool such data but would discuss issues. We know of no supporting research for this 10% cut off but are investigating use of prediction intervals as an alternative to this unsatisfactory state.</P><P>When unanticipated clinical or methodological heterogeneity were obvious, we simply discussed. We did not undertake sensitivity analyses relating to these.</P></SUBSECTION></SUBGROUP_ANALYSIS><SENSITIVITY_ANALYSIS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="4">1. Implication of randomisation</HEADING><P>If trials were described in some way as to imply randomisation we undertook a sensitivity analysis for the primary outcomes. We included these studies in the analyses and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we used relevant data from these studies.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2. Assumptions for lost binary data</HEADING><P>Where assumptions had to be made regarding people lost to follow-up (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>) we compared the findings of the primary outcomes when we used our assumption compared with 'completer' data only. If there was a substantial difference, we reported and discussed these results but continued to employ our assumption.</P><P>Where assumptions have to be made regarding missing SDs data (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>), we compared the findings on primary outcomes when we used our assumption compared with 'completer' data only. We undertook a sensitivity analysis testing how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported and discussed these results but continued to employ our assumption.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">3. Risk of bias</HEADING><P>We analysed the effects of excluding trials that we judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available), allocation concealment, blinding and outcome reporting for the meta-analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, we included data from these trials in the analysis.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">4. Imputed values</HEADING><P>Had cluster trials been included, we would have undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect.</P><P>If we found substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">5. Fixed and random effects</HEADING><P>We synthesised data using a fixed-effect model; however, we also synthesised data for the primary outcome using a random-effects model to evaluate whether this altered the significance of the results.</P></SUBSECTION></SENSITIVITY_ANALYSIS></DATA_COLLECTION></METHODS><RESULTS MODIFIED="2018-01-17 13:54:16 +0000" MODIFIED_BY="[Empty name]"><STUDY_DESCRIPTION MODIFIED="2018-01-17 13:54:16 +0000" MODIFIED_BY="[Empty name]"><P>Please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>.</P><SEARCH_RESULTS MODIFIED="2017-12-19 13:19:06 +0000" MODIFIED_BY="[Empty name]"><P>The 2015 and 2017 update searches were part of an update search of nine Cochrane Reviews; see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. The 2015 search retrieved 704 references for 344 studies; see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> for study flow diagram. After excluding irrelevant references at title and abstract screening, we screened full texts of 31 references (25 studies). As a result of updating the methods and outcomes considered in this review, we have now included two studies that we previously excluded because of a lack of placebo control (<LINK REF="STD-Bucci-1971" TYPE="STUDY">Bucci 1971</LINK>), and uncertainty around the number of participants (<LINK REF="STD-Greil-1984" TYPE="STUDY">Greil 1984</LINK>); see <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK>. These two studies are the only studies included in this review. One study is awaiting classification (<LINK REF="STD-Zeng-1996" TYPE="STUDY">Zeng 1996</LINK>).</P><P>The 2017 search found eight records (five studies). Editorial base of Cochrane Schizophrenia screened these records and no new studies were relevant to this review. They could be relevant to the other reviews in this series of TD reviews (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>), and have been put into 'Studies awaiting classification' of the <LINK REF="REF-Soares_x002d_Weiser-2003" TYPE="REFERENCE">Soares-Weiser 2003</LINK> 'miscellaneous treatments' review.</P></SEARCH_RESULTS><INCLUDED_STUDIES_DESCR MODIFIED="2018-01-17 13:54:16 +0000" MODIFIED_BY="[Empty name]"><P>The review now includes two studies with 30 participants, published in 1971 and 1984.</P><SUBSECTION><HEADING LEVEL="4">1. Methods</HEADING><P>Both studies were stated to be randomised and <LINK REF="STD-Greil-1984" TYPE="STUDY">Greil 1984</LINK> also reported being double blind. For further details, please see <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK> (below) on allocation and blinding.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2. Design</HEADING><P>Both studies presented a parallel longitudinal design.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">3. Duration</HEADING><P>The study by <LINK REF="STD-Greil-1984" TYPE="STUDY">Greil 1984</LINK> lasted for 7 weeks while <LINK REF="STD-Bucci-1971" TYPE="STUDY">Bucci 1971</LINK> lasted 40 weeks.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">4. Participants</HEADING><P>Participants, totalling 30 people, were mostly women in their 50s, with diagnoses of chronic schizophrenia. All were reported to have antipsychotic-induced TD; however, no criteria for the diagnosis of TD were reported. The number of participants ranged from 10 (<LINK REF="STD-Greil-1984" TYPE="STUDY">Greil 1984</LINK>) to 20 (<LINK REF="STD-Bucci-1971" TYPE="STUDY">Bucci 1971</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">5. Setting</HEADING><P>One study was performed in hospital outpatients in the USA (<LINK REF="STD-Bucci-1971" TYPE="STUDY">Bucci 1971</LINK>); the other was set in Germany but did not report whether participants were
 out- or inpatients
 (<LINK REF="STD-Greil-1984" TYPE="STUDY">Greil 1984</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">6. Interventions</HEADING><SUBSECTION><HEADING LEVEL="5">6.1 Anticholinergic medications</HEADING><SUBSECTION><HEADING LEVEL="6">6.1.1 Procyclidine</HEADING><P>Procyclidine was used by <LINK REF="STD-Bucci-1971" TYPE="STUDY">Bucci 1971</LINK> in a 5 mg dose, twice daily.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="6">6.1.2 Biperiden</HEADING><P>Biperiden was used by <LINK REF="STD-Greil-1984" TYPE="STUDY">Greil 1984</LINK> in the same dose that participants received before the trial. This trial compared the withdrawal of biperiden after 1 week and 4 weeks.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="5">6.2 Comparison group</HEADING><P><LINK REF="STD-Greil-1984" TYPE="STUDY">Greil 1984</LINK> compared the withdrawal of biperiden over two time periods. <LINK REF="STD-Bucci-1971" TYPE="STUDY">Bucci 1971</LINK> used isocarboxazid &#8212; a monoamine oxidase inhibitor &#8212; 10 mg twice per day as a control.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="4">7. Outcomes</HEADING><SUBSECTION><HEADING LEVEL="5">7.1 TD symptoms</HEADING><P>Only one study provided useable data on TD symptoms (<LINK REF="STD-Bucci-1971" TYPE="STUDY">Bucci 1971</LINK>). This appears to be a clinical assessment and not a validated scale.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">7.2 Adverse events</HEADING><P>Only one study provided useable data on adverse events as a result of medication (<LINK REF="STD-Bucci-1971" TYPE="STUDY">Bucci 1971</LINK>). This was reported simply as the number of events in both groups.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Studies awaiting classification</HEADING><P>We identified one study, published in Chinese (<LINK REF="STD-Zeng-1996" TYPE="STUDY">Zeng 1996</LINK>). We have contacted the study authors to determine if participants were diagnosed with TD but at the time of preparing this review we had not had a response.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Ongoing studies</HEADING><P>We have identified no ongoing studies.</P></SUBSECTION></INCLUDED_STUDIES_DESCR><EXCLUDED_STUDIES_DESCR MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>There are 22 excluded studies. Twelve studies were not randomised (<LINK REF="STD-Casey-1977" TYPE="STUDY">Casey 1977</LINK>; <LINK REF="STD-Gardos-1984" TYPE="STUDY">Gardos 1984</LINK>; <LINK REF="STD-Gerlach-1976" TYPE="STUDY">Gerlach 1976</LINK>; <LINK REF="STD-Gerlach-1978" TYPE="STUDY">Gerlach 1978</LINK>; <LINK REF="STD-Jus-1974" TYPE="STUDY">Jus 1974</LINK>; <LINK REF="STD-Konig-1996" TYPE="STUDY">Konig 1996</LINK>; <LINK REF="STD-Lejoyeux-1993" TYPE="STUDY">Lejoyeux 1993</LINK>; <LINK REF="STD-Smith-1979" TYPE="STUDY">Smith 1979</LINK>; <LINK REF="STD-Tamminga-1977" TYPE="STUDY">Tamminga 1977</LINK>; <LINK REF="STD-Wirshing-1989a" TYPE="STUDY">Wirshing 1989a</LINK>; <LINK REF="STD-Wirshing-1989b" TYPE="STUDY">Wirshing 1989b</LINK>; <LINK REF="STD-Zwanikken-1976" TYPE="STUDY">Zwanikken 1976</LINK>). Four studies were randomised but included participants with schizophrenia but not TD (<LINK REF="STD-DiMascio-1976" TYPE="STUDY">DiMascio 1976</LINK>; <LINK REF="STD-Double-1993" TYPE="STUDY">Double 1993</LINK>; <LINK REF="STD-Elie-1972" TYPE="STUDY">Elie 1972</LINK>; <LINK REF="STD-Fann-1976" TYPE="STUDY">Fann 1976</LINK>). One study did not report data separately on the minority of participants with TD and the author confirmed that these data are unavailable (<LINK REF="STD-Klett-1972" TYPE="STUDY">Klett 1972</LINK>). Four studies were cross-over trials that did not provide data before the first phase before crossing over to the next treatment. We contacted authors of three of these studies and received no data (<LINK REF="STD-Friis-1983" TYPE="STUDY">Friis 1983</LINK>; <LINK REF="STD-Lieberman-1988" TYPE="STUDY">Lieberman 1988</LINK>; <LINK REF="STD-NDSG-1986" TYPE="STUDY">NDSG 1986</LINK>). For one of these studies we were not able to identify up-to-date contact details, and we consider it is very unlikely that we will receive a reply with data so many years later (<LINK REF="STD-Silver-1995" TYPE="STUDY">Silver 1995</LINK>). One study did not provide any usable data, despite our making contact with the authors (<LINK REF="STD-Ludatscher-1989" TYPE="STUDY">Ludatscher 1989</LINK>).</P></EXCLUDED_STUDIES_DESCR></STUDY_DESCRIPTION><STUDY_QUALITY MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Please refer to <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for graphical overviews of the risk of bias in the included studies.</P><ALLOCATION MODIFIED="2016-11-18 14:00:56 +0000" MODIFIED_BY="[Empty name]"><P>While both studies claimed to be randomised, neither described explicitly how the randomisation sequence was generated or how allocation concealment was ensured. As a result we have rated them as having unclear risk of bias.</P></ALLOCATION><BLINDING MODIFIED="2016-10-18 13:46:36 +0100" MODIFIED_BY="[Empty name]"><P>Although <LINK REF="STD-Greil-1984" TYPE="STUDY">Greil 1984</LINK> was conducted on a double-blind basis, only blinding of the treatment provider was explicitly described. <LINK REF="STD-Bucci-1971" TYPE="STUDY">Bucci 1971</LINK> did not mention blinding of providers, participants, or outcome assessors. </P></BLINDING><EXCLUSIONS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>In each included study there was one person who did not complete the study. In all cases, however, we tried to ensure that every person randomised was analysed.</P></EXCLUSIONS><SELECTIVE_REPORTING MODIFIED="2016-11-27 11:18:18 +0000" MODIFIED_BY="[Empty name]"><P>All data in this review originates from published reports. The expected outcomes (impact on TD symptoms) were not reported sufficiently by <LINK REF="STD-Greil-1984" TYPE="STUDY">Greil 1984</LINK>. Both studies did not fully report outcomes that were measured during the study and were rated at high risk of reporting bias. Attempts to contact authors of trials for additional data were unsuccessful.</P></SELECTIVE_REPORTING><OTHER_BIAS_SOURCES MODIFIED="2016-10-18 13:46:48 +0100" MODIFIED_BY="[Empty name]"><P>Both studies had very small sample sizes. There was very little information reported on which to base further concerns regarding risk of bias. </P></OTHER_BIAS_SOURCES></STUDY_QUALITY><INTERVENTION_EFFECTS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="3">1. Comparison 1: anticholinergic drugs versus placebo or no treatment</HEADING><P>No studies were identified that assessed this comparison.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">2. Comparison 2: anticholinergic drugs versus other compounds</HEADING><SUBSECTION><HEADING LEVEL="4">2.1 TD symptoms</HEADING><P>We had chosen 'any improvement in TD symptoms of more than 50% on any TD scale &#8210; any time period' as a primary outcome. Although the data we found in trials did not fit this exactly we feel that the outcome 'not improved to a clinically important extent' fits best with what we had hoped to find.</P><SUBSECTION><HEADING LEVEL="5">2.1.1 Not improved to a clinically important extent</HEADING><P>One study found a significant difference on 'no clinically important improvement in TD symptoms favouring isocarboxazid (MAO-inhibitor) compared with procyclidine (anticholinergic) after 40 weeks' (low-quality evidence, 1 trial, 20 people; RR 4.20, 95% CI 1.40 to 12.58; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2.1.2 Not any improvement</HEADING><P>For the outcome of 'not any improvement in TD symptoms', procyclidine resulted in a worse outcome than isocarboxazid after 40 weeks (low-quality evidence, 1 trial, 20 people; RR 7.00, 95% CI 1.57 to 31.15; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2.2 Adverse effects</HEADING><SUBSECTION><HEADING LEVEL="5">2.2.1 Any adverse effects</HEADING><P>There was no significant difference in the incidence of any adverse effects between procyclidine and isocarboxazid after 40 weeks (very low quality evidence, 1 trial, 20 people; RR 0.33, 95% CI 0.02 to 7.32; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2.3 Leaving the study early</HEADING><P>Using procyclidine did not significantly affect the chances of a person leaving the study early compared to isocarboxazid after 40 weeks (very low quality evidence, 1 trial, 20 people; RR 0.33, 95% CI 0.02 to 7.32; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P><P>We did not identify any studies that reported on hospital and service utilisation outcomes, economic outcomes, social confidence, social inclusion, social networks, personalised quality of life, behaviour, or cognitive state.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">3. Comparison 3: continuation versus withdrawal of anticholinergic drugs</HEADING><SUBSECTION><HEADING LEVEL="4">3.1 Leaving the study early</HEADING><P>The only usable data showed no significant difference on leaving the study early between withdrawal of biperiden after 1 week compared with continuation of the drug for 4 weeks (very low quality evidence, 1 trial, 10 people; RR 2.14, 95% CI 0.11 to 42.52; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P><P>We did not identify any studies that reported on TD symptoms, adverse events, hospital and service utilisation outcomes, economic outcomes, social confidence, social inclusion, social networks, personalised quality of life, behaviour, or cognitive state.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">4. Subgroup analyses</HEADING><SUBSECTION><HEADING LEVEL="4">4.1 Clinical stage: recent onset TD</HEADING><P>It was not possible to evaluate whether those with recent onset TD responded differently to those with more established problems, since no trial reported data for groups with different durations of TD that could be extracted for separate analyses, and since only one study per comparison was included.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">4.2 Duration of follow-up</HEADING><P>It was not possible to evaluate whether the effect of anticholinergic drugs changed in relation to duration of follow-up; only one study per comparison was included.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">5. Heterogeneity</HEADING><P>Only one study per comparison was included. Therefore, investigation into heterogeneity was not relevant, and we could not detect clinical, methodological or statistical heterogeneity as described in <LINK TAG="HETEROGENEITY_ASSESSMENT" TYPE="SECTION">Assessment of heterogeneity</LINK>.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">6. Sensitivity analyses</HEADING><SUBSECTION><HEADING LEVEL="5">6.1 Implication of randomisation</HEADING><P>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. We have not undertaken this sensitivity analysis as only one study was included per comparison, and both studies were stated to be randomised.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">6.2 Assumptions for lost binary data</HEADING><P>Where assumptions had to be made regarding people lost to follow-up (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>) we compared the findings when we used our assumption with 'completer' data only. Using 'completer' data only for anticholinergic drugs (procyclidine) versus isocarboxazid, we found that there was no substantial alteration to the direction of effect or the precision of the effect estimates for the primary outcome 'no clinically important improvement' (1 trial, 19 people; RR 3.82, 95% CI 1.30 to 11.26; analysis not shown).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">6.3 Risk of bias</HEADING><P>It was not possible to evaluate whether excluding trials that we judged to be at high risk of bias across one or more of the domains would alter the effect estimate; only one study was included per comparison.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">6.4 Imputed values</HEADING><P>We would have undertaken a sensitivity analysis to assess the effects of including data from cluster randomised trials where we used imputed values for ICC in calculating the design effect. However, no cluster randomised trials were included.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">6.5 Fixed and random effects</HEADING><P>We also synthesised data for the primary outcome using a random-effects model. This did not alter the results.</P></SUBSECTION></SUBSECTION></INTERVENTION_EFFECTS></RESULTS><DISCUSSION MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUMMARY_OF_RESULTS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="3">1. The search</HEADING><P>This area of research does not seem to be active. The 2017 update has identified additional data, but all trials predate 1990. This could be because of reasons such as less concern with TD, or less emergence of the problem in research-active communities because of more thoughtful use of antipsychotic drugs.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">2. Few data</HEADING><P>Only 30 people were included in this review. For this reason it is very likely that real &#8212; and important &#8212; effects have not been highlighted because of the necessarily wide CIs of the findings. Many outcomes were not measured at all, including several of our pre-stated outcome measures (see <LINK TAG="APPLICABILITY_OF_FINDINGS" TYPE="SECTION">Overall completeness and applicability of evidence</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">3. Comparison 1: anticholinergic drugs versus placebo or no treatment</HEADING><P>We found no included study that compared the efficacy or safety of an anticholinergic drug compared with placebo or no treatment (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">4. Comparison 2: anticholinergic drugs versus other compounds</HEADING><P>We identified one very small trial reporting few outcomes (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). There were no data on mental state or social outcomes.</P><SUBSECTION><HEADING LEVEL="4">4.1 TD symptoms</HEADING><P>One study found that more participants on isocarboxazid (MAO-inhibitor) than on procyclidine (anticholinergic) improved to a clinically important level at long term (RR 4.20, 95% CI 1.40 to 12.58; N = 20). However, the quality of the evidence is very low and therefore we have very little confidence in the effect estimate and CIs &#8212; the true effect is likely to be substantially different.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">4.2 Adverse effects</HEADING><P>One study found no clear difference in adverse events between procyclidine (anticholinergic) (0/10) and isocarboxazid (MAO-inhibitor) (1/10) (RR 0.33, 95% CI 0.02 to 7.32; N = 20). Evidence was of very low quality, therefore we are uncertain about the result.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">4.3 Leaving the study early</HEADING><P>One study found no clear difference in leaving the study early between procyclidine (anticholinergic) (0/10) and isocarboxazid (MAO-inhibitor) (1/10) (RR 0.33, 95% CI 0.02 to 7.32; N = 20). Evidence was of very low quality, therefore we are uncertain about the result.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">5. Comparison 3. continuation versus withdrawal of anticholinergic drugs</HEADING><P>We identified one very small trial reporting few outcomes (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). There were no data on tardive dyskinesia, adverse effects, mental state or social outcomes.</P><SUBSECTION><HEADING LEVEL="4">5.1 Leaving the study early</HEADING><P>One study found no significant difference in leaving the study early between anticholinergic withdrawal after 1 week (1/6) and anticholinergic continuation for 4 weeks (0/4) (RR 2.14, 95% CI 0.11 to 42.52; N = 10). Evidence was of very low quality, therefore we are uncertain about the result.</P></SUBSECTION></SUBSECTION></SUMMARY_OF_RESULTS><APPLICABILITY_OF_FINDINGS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="3">1. Completeness</HEADING><P>Only two small studies with few useable data were included, not sufficient to address whether the use or withdrawal of anticholinergic drugs was associated with an improvement in antipsychotic-induced TD in people with schizophrenia or other chronic mental illness, let alone to examine whether there was a differential effect among the different anticholinergic drugs. We only identified usable data on TD symptoms from a study comparing anticholinergic medication with another compound, the antidepressant isocarboxazid, a drug which is experimental in the treatment of TD. We found few usable data on adverse events, and none on mental state, social confidence, social inclusion, social networks, or personalised quality of life. If reporting had been better we might have been able to include more data from these studies, and we might have had some data to present from the excluded studies (<LINK REF="STD-Friis-1983" TYPE="STUDY">Friis 1983</LINK>; <LINK REF="STD-Lieberman-1988" TYPE="STUDY">Lieberman 1988</LINK>; <LINK REF="STD-Ludatscher-1989" TYPE="STUDY">Ludatscher 1989</LINK>; <LINK REF="STD-NDSG-1986" TYPE="STUDY">NDSG 1986</LINK>; <LINK REF="STD-Silver-1995" TYPE="STUDY">Silver 1995</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">2. Applicability</HEADING><P>Trials included both in- and outpatients who were mostly women in their 50s with schizophrenia. They were people who would be recognisable in everyday care. The interventions in question &#8212; anticholinergic drugs &#8212; are readily accessible and most outcomes are understandable in terms of clinical practice. Should anticholinergic drugs have had important effects the findings might well have been applicable.</P></SUBSECTION></APPLICABILITY_OF_FINDINGS><QUALITY_OF_EVIDENCE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>We cannot draw any robust conclusions regarding the effects of anticholinergic drugs on TD: only two studies with 30 participants could be included, which severely limited the quality of the evidence. The larger trial randomised only 20 people: a trial of this size is unable to detect subtle, yet important, differences due to an intervention with any confidence. In order to detect a 20% difference between groups, probably about 150 people are needed in each arm of the study (alpha 0.05, beta 0.8). Overall the quality of reporting of these trials was poor (see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Allocation concealment was not described, generation of the sequence was not explicit, studies were not clearly blinded, and data were not fully reported. The small sample size and the poor reporting means that we have very little confidence in the effect estimates, and the true effects are likely to be substantially different from the estimates of the effects.</P></QUALITY_OF_EVIDENCE><POTENTIAL_BIASES MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="3">1. Missing studies</HEADING><P>We made every effort to identify relevant trials. However, these studies are both small and it is likely that we have failed to identify other studies of limited power. It is likely that such studies would also not be in favour of the anticholinergics group: if they had been so, it is more likely that they would have been published in accessible literature. We do not, however, think it likely that we have failed to identify large relevant studies.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">2. Introducing bias</HEADING><P>We have tried to be balanced in our appraisal of the evidence but could have inadvertently introduced bias. We welcome comments or criticisms. New methods and innovations now make it possible to report data where, in the past, we could not report data at all or had to report data in a different way. We believe 'Summary of findings' table is a valuable innovation but problematic to those not &#8216;blind&#8217; to the outcome data: it is possible to &#8216;cherry pick&#8217; significant findings for presentation in this table. We have tried to decrease the chance of doing this by asking a new reviewer (HB) to select outcomes relevant for this table before becoming familiar with the data.</P></SUBSECTION></POTENTIAL_BIASES><AGREEMENT MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>The only other relevant quantitative review we know of is the previous Cochrane Review (<LINK REF="REF-Soares_x002d_Weiser-1997" TYPE="REFERENCE">Soares-Weiser 1997</LINK>). This update identified two studies to include (as discussed in <LINK TAG="SEARCH_RESULTS" TYPE="SECTION">Results of the search</LINK> and <LINK TAG="POTENTIAL_BIASES" TYPE="SECTION">Potential biases in the review process</LINK>), but the very sparse and low-quality evidence lead to no substantial change in the conclusions.</P></AGREEMENT></DISCUSSION><CONCLUSIONS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><IMPLICATIONS_PRACTICE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="3">1. For people with TD</HEADING><P>Based on the currently available data, this systematic review can provide no useful information for service-users about the use of anticholinergics (benzhexol, benztropine, biperiden, orphenadrine, procyclidine, scopolamine or trihexylphenidyl) for the treatment of antipsychotic-induced TD. In addition, there is no evidence to support the suggestion that the withdrawal of these medications may benefit people with TD. People with TD could consider these as other experimental treatments for which very little supportive data exist. Few data exist for any treatment for TD.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">2. For clinicians</HEADING><P>Anticholinergics have been widely used in modern psychiatry for the treatment of extrapyramidal side effects (EPS). There is some suggestion that they may exacerbate TD symptoms; however, the link between the use of anticholinergics and the emergence of TD may be only an epiphenomenon, since people who develop EPS are thought to be more likely to receive anticholinergics and also to develop TD (<LINK REF="REF-APA-1992" TYPE="REFERENCE">APA 1992</LINK>). Nevertheless, based on this systematic review there is no solid evidence to support or discourage the use or withdrawal of these medications as a treatment for TD. There is a real place for clinician-driven research, with prescription within the context of a randomised trial and routine data collection on outcomes of relevance to people with TD and their clinicians.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">3. Policy makers or managers</HEADING><P>This is one of the reviews in the series of Cochrane Reviews on treatments for antipsychotic-induced TD (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). No evidence is convincing that addition or withdrawal of another drug helps with the symptoms of TD. There are, however, many unanswered questions in this area. This unattractive adverse effect is caused, to a greater or lesser extent, by antipsychotic drugs. Clinicians and researchers should feel responsible enough to continue to try to help it. Those compiling guidance could encourage supportive activity and more research into this neglected area.</P></SUBSECTION></IMPLICATIONS_PRACTICE><IMPLICATIONS_RESEARCH MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="3">1. General</HEADING><P>The power of this review would have been greatly enhanced by better reporting of data. For example, none of the trials made explicit how randomisation was undertaken. We realise that the work for these trials predates <A HREF="http://www.consort-statement.org/">CONSORT</A>, which was first published in 1996 (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>), and that it is only too easy to judge studies of the past by standards of today. Future studies, however, should report to a much higher standard.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">2. Specific</HEADING><P>From the theoretical background, there is some evidence to suggest that withdrawal of anticholinergics may benefit people with antipsychotic-induced TD. Well-designed randomised controlled trials, involving a large number of participants over protracted periods of time, are needed if we are to see if anticholinergics or anticholinergic withdrawal could have a role in prevention and treatment of TD. Such studies are of importance to people with the problem and have long been ignored (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P><SUBSECTION><HEADING LEVEL="4">2.1 Use of cross-over design</HEADING><P>Trialists find it difficult to identify people with both TD and schizophrenia to participate in trials. Randomised cross-over design is used in the hope of improving the power of the study to find outcomes of interest. This design initially asks participants to be randomised to one of the experimental interventions, and then, at a pre-specified time, to be crossed over to the treatment that they did not at first receive. Conditions with a more stable time course than TD are better suited for cross-over studies (<LINK REF="REF-Fleiss-1984" TYPE="REFERENCE">Fleiss 1984</LINK>). Further difficulties are the carry-over effect and a related neuroreceptor issue. Unless cross-over studies include a mid-study washout period (where the person is free of treatment before starting the next arm of the study), any effect of anticholinergic drugs may continue into the second half placebo arm of the trial &#8212; the 'carry-over effect'. Also, carry-over may involve the re-growth or retreat of neuroreceptors. This slow re-balancing, if started, could continue long after all traces of intervention drugs are gone, so physiological half life of the experimental treatment may not be the only variable to consider when thinking though the issues of carry-over. TD is also an unstable condition and people with TD may not remain compliant with medication. All these factors make the arguments for not using cross-over methodology strong, despite the initial attraction (<LINK REF="REF-Armitage-1991" TYPE="REFERENCE">Armitage 1991</LINK>; <LINK REF="REF-Fleiss-1984" TYPE="REFERENCE">Fleiss 1984</LINK>; <LINK REF="REF-Pocock-1983" TYPE="REFERENCE">Pocock 1983</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2.2 Sample size calculation</HEADING><P>None of the trials explained how they calculated their sample size. However, the results suggest that larger sample size should be used to provide more precise estimates of effect.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2.3 Length of study</HEADING><P>One of the studies included in this review used the intervention for 40 weeks (<LINK REF="STD-Bucci-1971" TYPE="STUDY">Bucci 1971</LINK>). TD is a chronic condition of insidious onset, the severity of which fluctuates spontaneously (<LINK REF="REF-APA-1992" TYPE="REFERENCE">APA 1992</LINK>). Even if anticholinergics or anticholinergic withdrawal has a swift effect, which is unlikely, it is the long-term outcomes that must be considered of most clinical value.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2.4 Outcomes</HEADING><P>Many of the outcomes we initially desired when we started this review have not been investigated. In addition, a service user consultation also informed the addition of outcomes of special importance to patients. We have reconsidered all these outcomes in case they were too ambitious and tried to tailor them to a real-world pragmatic trial design (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P></SUBSECTION></SUBSECTION></IMPLICATIONS_RESEARCH></CONCLUSIONS></BODY><ACKNOWLEDGEMENTS MODIFIED="2018-01-17 14:04:59 +0000" MODIFIED_BY="[Empty name]"><P>The Cochrane Schizophrenia Group Editorial Base in Nottingham produces and maintains standard text for use in the Methods sections of their reviews. We have used this text as the basis of what appears here and adapted it as required.</P><P><I>Previous versions</I></P><P>The authors wish to thank John McGrath who was involved in protocol development, searching, data extraction, data assimilation and report writing in previous versions of this review. </P><P>The authors wish to thank Dr Gardos, Dr Greil and Dr Klett for their support with more information regarding their trials. Kirsten Mason and Leanne Roberts helped in the collection of the papers.</P><P>We also wish to acknowledge and thank Caroline Mobsy and Eleanor Holliday for their contributions to earlier versions of this review.</P><P><I>2017 Update</I></P><P>Parts of this review were generated using RevMan HAL v 4.0. You can find more information about RevMan HAL <A HREF="http://schizophrenia.cochrane.org/revman-hal-v4">here</A>.</P><P>We wish to thank Rosie Asher for screening literature and helping with data extraction. We also thank Antonio Grande for helping with data extraction, Nicholas Henschke and Loukia Spineli for assisting with updating the report, and Ben Gray for writing the Plain Language Summary. We are also grateful to Dawn-Marie Walker, Ruth Sayers, Megan Lees, and Vanessa Pinfold from <A HREF="http://mcpin.org/">McPin Foundation</A> for organising and holding the public- and patient-involvement consultation with TD service users that contributed to selecting outcomes for the 'Summary of findings' tables and to guide future research. We also wish to thank Farhad Sokraneh at the Cochrane Schizophrenia Group editorial base for conducting the 2015 update search and helping in the collection of the papers.</P></ACKNOWLEDGEMENTS><CONFLICT_OF_INTEREST MODIFIED="2018-01-15 16:02:27 +0000" MODIFIED_BY="[Empty name]"><P>Hanna Bergman worked for Enhance Reviews Ltd. during preparation of this review and was paid for her contribution to this review. Enhance Reviews Ltd. is a private company that performs systematic reviews of literature. HB works for Cochrane Response, an evidence consultancy linked to Cochrane that take commissions from healthcare guideline developers and policy makers.</P><P>Karla Soares-Weiser is the Deputy Editor-in-Chief for Cochrane and Cochrane Innovations. When the NHIR HTA programme grant was awarded that included provision to update this review, Karla was the Managing Director of Enhance Reviews Ltd.</P></CONFLICT_OF_INTEREST><CONTRIBUTIONS MODIFIED="2018-01-15 16:01:53 +0000" MODIFIED_BY="[Empty name]"><P>HB - trial selection, data extraction and assimilation, 'Summary of findings' tables, report writing.</P><P>KSW - protocol writing, searching, trial selection, data extraction and assimilation, report writing.</P></CONTRIBUTIONS><PRO_REV_DIFF MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>The protocol as published with this review has evolved over time. The revisions of protocol are in line with the development of RevMan and in keeping with Cochrane guidance. We think the revisions have greatly improved and enhanced this review. We do not think, however, that it has materially affected our conduct of the review or interpretation of the results.</P><P>There was a substantial update to the protocol in the 2017 review update with main changes being as follows.</P><OL><LI>Broadening the inclusion criteria, and adding the comparison 'Anticholinergic medication vs any other intervention'.</LI><LI>Changing the title from 'Anticholinergic medication for neuroleptic-induced tardive dyskinesia' to the current title.</LI><LI>Rewording of the objectives.</LI><LI>Updating list of outcomes following consultation with consumers.</LI><LI>Adding 'Summary of findings' tables.</LI></OL><P>The previous methods are reproduced in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P></PRO_REV_DIFF><PUBLIC_NOTES><P>Cochrane schizophrenia Group internal peer review complete (see Module).<BR/>External peer review scheduled.</P></PUBLIC_NOTES></MAIN_TEXT><STUDIES_AND_REFERENCES MODIFIED="2018-01-17 14:06:12 +0000" MODIFIED_BY="Claire Irving">
<STUDIES MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-07-12 12:31:55 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bucci-1971" MODIFIED="2016-06-29 21:33:28 +0100" MODIFIED_BY="[Empty name]" NAME="Bucci 1971" YEAR="1971">
<REFERENCE MODIFIED="2016-06-29 21:33:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bucci L</AU>
<TI>The dyskinesias: a new therapeutic approach</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1971</YR>
<VL>32</VL>
<NO>5</NO>
<PG>324-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230268"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230267"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greil-1984" MODIFIED="2016-07-06 09:15:24 +0100" MODIFIED_BY="[Empty name]" NAME="Greil 1984" YEAR="1984">
<REFERENCE MODIFIED="2016-07-06 09:15:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greil W, Haag H, Rossnagl G, Rüther E</AU>
<TI>Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1984</YR>
<VL>145</VL>
<PG>304-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230264"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230263"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Casey-1977" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Casey 1977" YEAR="1977">
<REFERENCE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casey DE, Denney D</AU>
<TI>Pharmacological characterization of tardive dyskinesia</TI>
<SO>Psychopharmacology</SO>
<YR>1977</YR>
<VL>54</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230270"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230269"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DiMascio-1976" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="DiMascio 1976" YEAR="1976">
<REFERENCE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE</AU>
<TI>A controlled trial of amantadine in drug-induced extrapyramidal disorders</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1976</YR>
<VL>33</VL>
<NO>5</NO>
<PG>599-602</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7481732"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-05-31 10:10:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE</AU>
<TI>A controlled trial of amantadine in drug-induced extrapyramidal disorders</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1977</YR>
<VL>13</VL>
<NO>3</NO>
<PG>31-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7481733"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230271"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Double-1993" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Double 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Double DB, Warren GC, Evans M, Rowlands MP</AU>
<TI>Efficacy of maintenance use of anticholinergic agents</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>88</VL>
<NO>5</NO>
<PG>381-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230293"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230292"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elie-1972" MODIFIED="2016-05-31 20:43:36 +0100" MODIFIED_BY="[Empty name]" NAME="Elie 1972" YEAR="1972">
<REFERENCE MODIFIED="2016-05-31 20:43:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elie R, Morin L, Tetreault M</AU>
<TI>Effects of ethopropazine and of trihexyphenidyl on several parameters of the neuroleptic syndrome</TI>
<SO>Encephale</SO>
<YR>1972</YR>
<VL>61</VL>
<NO>1</NO>
<PG>32-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230296"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230295"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fann-1976" NAME="Fann 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fann WE, Lake CR</AU>
<TI>Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1976</YR>
<VL>133</VL>
<NO>8</NO>
<PG>940-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230274"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230273"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friis-1983" NAME="Friis 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friis T, Christensen R, Gerlach J</AU>
<TI>Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1983</YR>
<VL>67</VL>
<NO>3</NO>
<PG>178-87</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230276"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230275"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gardos-1984" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Gardos 1984" YEAR="1984">
<REFERENCE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gardos G, Cole JO, Rapkin RM, LaBrie RA, Baquelod E, Moore P, et al</AU>
<TI>Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1984</YR>
<VL>41</VL>
<NO>11</NO>
<PG>1030-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230298"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230297"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerlach-1976" MODIFIED="2016-05-22 12:48:48 +0100" MODIFIED_BY="[Empty name]" NAME="Gerlach 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J, Thorsen K</AU>
<TI>The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment</TI>
<SO>Internal Pharmacopsychiatry</SO>
<YR>1976</YR>
<VL>11</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230278"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J</AU>
<TI>The relationship betwen parkisonism and tardive dyskinesia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1977</YR>
<VL>134</VL>
<NO>7</NO>
<PG>781-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230279"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230277"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerlach-1978" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Gerlach 1978" YEAR="1978">
<REFERENCE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J, Simmelsgaard H</AU>
<TI>Tardive dyskinesia during and following treatment with haloperidol, haloperidol and biperiden, thioridazine and clozapine</TI>
<SO>Psychopharmacology</SO>
<YR>1978</YR>
<VL>59</VL>
<NO>2</NO>
<PG>105-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7481735"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7481734"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jus-1974" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Jus 1974" YEAR="1974">
<REFERENCE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jus K, Jus A, Gautier J, Villeneuve A, Pires P, Pineau R, et al</AU>
<TI>Studies on the action of certain pharmacological agents on tardive dyskinesia and on the rabbit syndrome</TI>
<SO>International Journal of Clinical Pharmacology, Therapy, and Toxicology</SO>
<YR>1974</YR>
<VL>9</VL>
<NO>2</NO>
<PG>138-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230281"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230280"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klett-1972" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Klett 1972" YEAR="1972">
<REFERENCE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klett CJ, Caffey E</AU>
<TI>Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1972</YR>
<VL>26</VL>
<NO>4</NO>
<PG>374-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230283"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230282"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konig-1996" MODIFIED="2016-05-22 12:44:41 +0100" MODIFIED_BY="[Empty name]" NAME="Konig 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-05-22 12:44:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konig P, Chwatal K, Havelec L, Riedl F, Schubert H, Schultes H</AU>
<TI>Amantadine versus biperiden - a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders</TI>
<SO>Neuropsychobiology</SO>
<YR>1996</YR>
<VL>33</VL>
<NO>2</NO>
<PG>80-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230306"/><IDENTIFIER TYPE="MEDLINE" VALUE="8927233"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230305"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lejoyeux-1993" MODIFIED="2017-10-31 16:48:26 +0000" MODIFIED_BY="[Empty name]" NAME="Lejoyeux 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-10-31 16:48:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lejoyeux M, Gorwood P, Stalla-Bourdillon A, Ades J</AU>
<TI>Translation and application of the Simpson and Angus Scale of Extrapyramidal Symptoms</TI>
<TO>Traduction et utilisation de l'echelle de Simpson et Angus de symptomes extra-pyramidaux</TO>
<SO>L'Encéphale</SO>
<YR>1993</YR>
<VL>19</VL>
<NO>1</NO>
<PG>17-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230285"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230284"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lieberman-1988" MODIFIED="2016-07-12 12:29:09 +0100" MODIFIED_BY="[Empty name]" NAME="Lieberman 1988" YEAR="1988">
<REFERENCE MODIFIED="2016-07-12 12:29:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman J, Pollack S, Lesser M, Kane J</AU>
<TI>Pharmacologic characterization of tardive dyskinesia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>4</NO>
<PG>254-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230287"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230286"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ludatscher-1989" MODIFIED="2017-10-28 22:01:13 +0100" MODIFIED_BY="[Empty name]" NAME="Ludatscher 1989" YEAR="1989">
<REFERENCE MODIFIED="2017-10-28 22:01:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ludatscher JI</AU>
<TI>Stable remission of tardive dyskinesia by L-dopa</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>1</NO>
<PG>39-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7481737"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7481736"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NDSG-1986" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="NDSG 1986" YEAR="1986">
<REFERENCE MODIFIED="2016-05-31 20:33:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J, Ahfors UG, Amthor KF</AU>
<TI>Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol and biperiden</TI>
<SO>Psychopharmacology</SO>
<YR>1986</YR>
<VL>90</VL>
<NO>4</NO>
<PG>423-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230308"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-05-31 20:33:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J</AU>
<TI>Tardive dyskinesia: pathophysiological mechanisms and clinical trials</TI>
<SO>L'Encephale</SO>
<YR>1988</YR>
<VL>XIV</VL>
<PG>227-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230309"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nordik Dyskinesia Study Group</AU>
<TI>Effect of different neuroleptics in tardive dyskinesia and parkinsonism</TI>
<SO>Psychopharmacology</SO>
<YR>1986</YR>
<VL>90</VL>
<NO>4</NO>
<PG>423-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230310"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-05-31 20:33:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Povlsen UJ, Noring U, Meidahl B, Korsgaard S, Waehrens J, Gerlach J</AU>
<TI>Not available</TI>
<TO>Neuroleptikas virkning pa tardive dyskinesier</TO>
<SO>Ugeskr Laeger</SO>
<YR>1987</YR>
<VL>149</VL>
<NO>25</NO>
<PG>1682-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230311"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230307"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silver-1995" MODIFIED="2016-07-12 12:31:55 +0100" MODIFIED_BY="[Empty name]" NAME="Silver 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-07-12 12:31:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silver H, Geraisy N, Schwartz M</AU>
<TI>No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: A double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1995</YR>
<VL>56</VL>
<NO>9</NO>
<PG>435</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7481738"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-12 12:31:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Silver H, Geraisy N, Schwartz M</AU>
<TI>No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1995</YR>
<VL>56</VL>
<NO>4</NO>
<PG>167-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230266"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230265"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1979" MODIFIED="2016-07-06 10:29:34 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 1979" YEAR="1979">
<REFERENCE MODIFIED="2016-07-06 10:29:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith JS, Kiloh LG</AU>
<TI>Six-month evaluation of thiopropazate hydrochloride in tardive dyskinesia</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1979</YR>
<VL>42</VL>
<NO>6</NO>
<PG>576-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230289"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230288"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tamminga-1977" MODIFIED="2016-06-27 13:23:07 +0100" MODIFIED_BY="[Empty name]" NAME="Tamminga 1977" YEAR="1977">
<REFERENCE MODIFIED="2016-06-27 13:23:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tamminga CA, Smith RC, Ericksen SE, Chang S, Davis JM</AU>
<TI>Cholinergic influences in tardive dyskinesia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1977</YR>
<VL>134</VL>
<NO>7</NO>
<PG>769-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7481740"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7481739"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wirshing-1989a" MODIFIED="2017-10-31 16:50:03 +0000" MODIFIED_BY="[Empty name]" NAME="Wirshing 1989a" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wirshing WC, Freidenberg DL, Cummings JL, Bartzokis G</AU>
<TI>Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>6</NO>
<PG>407-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7481742"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7481741"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wirshing-1989b" MODIFIED="2017-10-31 16:49:57 +0000" MODIFIED_BY="[Empty name]" NAME="Wirshing 1989b" YEAR="1989">
<REFERENCE MODIFIED="2016-05-22 12:46:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wirshing WC, Freidenberg DL, Cummings JL, Bartzokis G</AU>
<TI>Effect of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>6</NO>
<PG>407-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7481744"/><IDENTIFIER TYPE="MEDLINE" VALUE="2574192"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7481743"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zwanikken-1976" MODIFIED="2016-05-22 12:46:26 +0100" MODIFIED_BY="[Empty name]" NAME="Zwanikken 1976" YEAR="1976">
<REFERENCE MODIFIED="2016-05-22 12:46:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zwanikken GJ, Oei TT, Kimya S, Amery W</AU>
<TI>Safety and efficacy of prolonged treatment with Tremblex (dexetimide), an antiparkinsonian agent. A controlled study</TI>
<SO>Acta Psychiatrica Belgica</SO>
<YR>1976</YR>
<VL>76</VL>
<NO>3</NO>
<PG>467-79</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3230321"/><IDENTIFIER TYPE="MEDLINE" VALUE="1020682"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3230320"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-07-06 10:32:45 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Zeng-1996" MODIFIED="2016-07-06 10:32:45 +0100" MODIFIED_BY="[Empty name]" NAME="Zeng 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-07-06 10:32:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhaoxiang Z, Fenglian C, Lin L</AU>
<TI>A Clinical Research of Dexetimide and Benzhexol for Treatment of Drug-induced Tremor</TI>
<SO>Herald of Medicine</SO>
<YR>1996</YR>
<VL>15</VL>
<NO>3</NO>
<PG>130-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7481746"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7481745"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2018-01-17 13:54:17 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2018-01-17 13:54:17 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alabed-2011" MODIFIED="2016-11-18 13:25:57 +0000" MODIFIED_BY="[Empty name]" NAME="Alabed 2011" TYPE="COCHRANE_REVIEW">
<AU>Alabed S, Latifeh Y, Mohammad HA, Rifai A</AU>
<TI>Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-11-18 13:25:57 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-11-18 13:25:57 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000203.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alphs-1983" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Alphs 1983" TYPE="JOURNAL_ARTICLE">
<AU>Alphs LD, Davis JM</AU>
<TI>Cholinergic treatments for tardive dyskinesia</TI>
<SO>Modern Problems in Pharmacopsychiatry</SO>
<YR>1983</YR>
<VL>21</VL>
<PG>168-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" MODIFIED="2016-01-18 10:59:07 +0000" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<NO>7066</NO>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1992" MODIFIED="2016-11-18 13:17:25 +0000" MODIFIED_BY="[Empty name]" NAME="APA 1992" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Tardive dyskinesia: a task force report of the American Psychiatric Association</SO>
<YR>1992</YR>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Armitage-1991" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Armitage 1991" TYPE="JOURNAL_ARTICLE">
<AU>Armitage P</AU>
<TI>Should we cross off the crossover?</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1991</YR>
<VL>32</VL>
<NO>1</NO>
<PG>1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1993" NAME="Barnes 1993" TYPE="BOOK_SECTION">
<AU>Barnes TRE, Edwards JG</AU>
<TI>The side-effects of antipsychotic drugs. I. CNS and neuromuscular effects</TI>
<SO>Antipsychotic drugs and their side-effects</SO>
<YR>1993</YR>
<ED>Barnes TRE</ED>
<PB>Harcourt Brace &amp; Company</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials: the CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bergen-1989" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Bergen 1989" TYPE="JOURNAL_ARTICLE">
<AU>Bergen JA, Eyland EA, Campbell JA</AU>
<TI>The course of tardive dyskinesia in patients on long-term neuroleptics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>523-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhoopathi-2006" MODIFIED="2016-10-19 07:58:00 +0100" MODIFIED_BY="[Empty name]" NAME="Bhoopathi 2006" TYPE="COCHRANE_REVIEW">
<AU>Bhoopathi PS, Soares-Weiser K</AU>
<TI>Benzodiazepines for neuroleptic-induced tardive dyskinesia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000205.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7108</NO>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2016-01-18 10:59:07 +0000" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<TO>Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite</TO>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS MODIFIED="2016-01-18 10:59:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="10667106"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Casey-1994" NAME="Casey 1994" TYPE="BOOK_SECTION">
<AU>Casey DE</AU>
<TI>Tardive dyskinesia: pathophysiology</TI>
<SO>Psychopharmacology. The Fourth Generation of Progress</SO>
<YR>1994</YR>
<ED>Bloom FE, Kupfer DJ</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cavallaro-1993" MODIFIED="2016-11-27 11:28:32 +0000" MODIFIED_BY="[Empty name]" NAME="Cavallaro 1993" TYPE="JOURNAL_ARTICLE">
<AU>Cavallaro R, Regazzetti MG, Mundo E, Brancato V, Smeraldi E</AU>
<TI>Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of Remission and persistence</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>3</NO>
<PG>233-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chouinard-2008" MODIFIED="2017-10-28 22:06:16 +0100" MODIFIED_BY="[Empty name]" NAME="Chouinard 2008" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Chouinard VA</AU>
<TI>Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes</TI>
<SO>Psychotherapy and Psychosomatics</SO>
<YR>2008</YR>
<VL>77</VL>
<NO>2</NO>
<PG>69-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cloud-2014" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Cloud 2014" TYPE="JOURNAL_ARTICLE">
<AU>Cloud LJ, Zutshi D, Factor SA</AU>
<TI>Tardive dyskinesia: therapeutic options for an increasingly common disorder</TI>
<SO>Neurotherapeutics</SO>
<YR>2014</YR>
<VL>11</VL>
<NO>1</NO>
<PG>166-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Correll-2004" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Correll 2004" TYPE="JOURNAL_ARTICLE">
<AU>Correll CU, Leucht S, Kane JM</AU>
<TI>Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<NO>3</NO>
<PG>414-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Correll-2008" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Correll 2008" TYPE="JOURNAL_ARTICLE">
<AU>Correll CU, Schenka EM</AU>
<TI>Tardive dyskinesia and new antipsychotics</TI>
<SO>Current Opinion in Psychiatry</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>2</NO>
<PG>151-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2016-01-18 10:59:07 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town</SO>
<YR>2000</YR>
<PB>The Cochrane Collaboration</PB>
<CY>Cape Town</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2016-01-18 10:59:07 +0000" MODIFIED_BY="[Empty name]" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>19</NO>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Sayeh-2006" MODIFIED="2016-10-19 07:58:00 +0100" MODIFIED_BY="[Empty name]" NAME="El-Sayeh 2006" TYPE="COCHRANE_REVIEW">
<AU>El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K</AU>
<TI>Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000458.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2016-01-18 10:59:07 +0000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Essali-2011" MODIFIED="2016-11-18 13:26:34 +0000" MODIFIED_BY="[Empty name]" NAME="Essali 2011" TYPE="COCHRANE_REVIEW">
<AU>Essali A, Deirawan H, Soares-Weiser K, Adams CE</AU>
<TI>Calcium channel blockers for neuroleptic-induced tardive dyskinesia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2016-11-18 13:26:34 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-11-18 13:26:34 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000206.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fernandez-2001" MODIFIED="2016-11-27 11:22:38 +0000" MODIFIED_BY="[Empty name]" NAME="Fernandez 2001" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez HH, Krupp B, Friedman JH</AU>
<TI>The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<PG>805-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleiss-1984" MODIFIED="2016-11-21 07:42:02 +0000" MODIFIED_BY="[Empty name]" NAME="Fleiss 1984" TYPE="BOOK_SECTION">
<AU>Fleiss JL</AU>
<TI>The crossover study</TI>
<SO>The Design and Analysis of Clinical Experiments</SO>
<YR>1984</YR>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2016-01-18 10:59:07 +0000" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>7</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glazer-1990" MODIFIED="2017-05-25 08:15:02 +0100" MODIFIED_BY="[Empty name]" NAME="Glazer 1990" TYPE="JOURNAL_ARTICLE">
<AU>Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC</AU>
<TI>Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>157</VL>
<PG>585-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glazer-2000" MODIFIED="2016-11-27 11:22:38 +0000" MODIFIED_BY="[Empty name]" NAME="Glazer 2000" TYPE="JOURNAL_ARTICLE">
<AU>Glazer WM</AU>
<TI>Review of incidence studies of tardive dyskinesia associated with typical antipsychotics</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>suppl 4</NO>
<PG>15-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<NO>9</NO>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeste-1982" NAME="Jeste 1982" TYPE="BOOK">
<AU>Jeste DV, Wyatt RJ</AU>
<SO>Understanding and treating tardive dyskinesia</SO>
<YR>1982</YR>
<PB>The Guilford Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1994" NAME="Kane 1994" TYPE="BOOK_SECTION">
<AU>Kane JM</AU>
<TI>Tardive dyskinesia: epidemiological and clinical presentation</TI>
<SO>Psychopharmacology. The Fourth Generation of Progress</SO>
<YR>1994</YR>
<ED>Bloom FE, Kupfer DJ</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2016-01-18 10:59:07 +0000" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and Negative Syndrome Scale (PANSS) Manual</SO>
<YR>1986</YR>
<PB>North Tonawanda, NY: Multi-Health Systems</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leon-2006" MODIFIED="2016-01-18 10:59:07 +0000" MODIFIED_BY="[Empty name]" NAME="Leon 2006" TYPE="JOURNAL_ARTICLE">
<AU>Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K</AU>
<TI>Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology</TI>
<SO>Biological Psychiatry</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>11</NO>
<PG>1001-5</PG>
<IDENTIFIERS MODIFIED="2016-01-18 10:59:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="16905632"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2017-10-28 22:15:50 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2016-01-18 10:59:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="15982856"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005b" MODIFIED="2017-10-28 22:15:43 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of brief psychiatric rating scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2016-01-18 10:59:04 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="16199797"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lieberman-1996" MODIFIED="2016-11-27 11:22:38 +0000" MODIFIED_BY="[Empty name]" NAME="Lieberman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Fleishhacker W</AU>
<TI>Introduction</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>168</VL>
<NO>Supplement 29</NO>
<PG>7-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" MODIFIED="2016-01-18 10:59:07 +0000" MODIFIED_BY="[Empty name]" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1999" MODIFIED="2012-08-01 12:50:02 +0100" MODIFIED_BY="[Empty name]" NAME="Mulrow 1999" TYPE="OTHER">
<AU>Mulrow CD, Oxman AD</AU>
<TI>Cochrane Collaboration Handbook [updated September 1999]</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1991</YR>
<NO>2</NO>
<PB>Update Software; 1996-. Updated quarterly</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2012-08-01 12:49:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-08-01 12:49:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="ATD020600"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NICE-2014" MODIFIED="2016-11-27 11:22:38 +0000" MODIFIED_BY="[Empty name]" NAME="NICE 2014" TYPE="OTHER">
<AU>NICE</AU>
<TI>Psychosis and schizophrenia in adults: treatment and management</TI>
<SO>NICE clinical guideline 178 (guidance.nice.org.uk/cg178)</SO>
<YR>2014</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2016-01-18 10:59:07 +0000" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The brief psychiatric rating scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pocock-1983" MODIFIED="2016-11-21 07:42:02 +0000" MODIFIED_BY="[Empty name]" NAME="Pocock 1983" TYPE="BOOK_SECTION">
<AU>Pocock SJ</AU>
<TI>Crossover trials</TI>
<SO>Clinical trials. A practical approach</SO>
<YR>1983</YR>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schooler-1993" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Schooler 1993" TYPE="JOURNAL_ARTICLE">
<AU>Schooler NR, Keith SJ</AU>
<TI>The clinical research base for the treatment of schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1993</YR>
<VL>29</VL>
<NO>4</NO>
<PG>431-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shokraneh-2017" MODIFIED="2018-01-17 13:54:17 +0000" MODIFIED_BY="[Empty name]" NAME="Shokraneh 2017" TYPE="JOURNAL_ARTICLE">
<AU>Shokraneh F, Adams CE</AU>
<TI>Study-based registers of randomized controlled trials: Starting a systematic review with data extraction or meta-analysis</TI>
<SO>BioImpacts</SO>
<YR>2017</YR>
<VL>7</VL>
<NO>4</NO>
<PG>209-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1980" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NAME="Smith 1980" TYPE="JOURNAL_ARTICLE">
<AU>Smith JM, Balessarini RJ</AU>
<TI>Changes in prevalence, severity and recovery in tardive dyskinesia with age</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1980</YR>
<VL>37</VL>
<NO>12</NO>
<PG>1368-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soares_x002d_Weiser-2003" MODIFIED="2016-10-19 07:58:00 +0100" MODIFIED_BY="[Empty name]" NAME="Soares-Weiser 2003" TYPE="COCHRANE_REVIEW">
<AU>Soares-Weiser K, Joy C</AU>
<TI>Miscellaneous treatments for neuroleptic-induced tardive dyskinesia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000208"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Soares_x002d_Weiser-2006" MODIFIED="2016-10-19 07:58:00 +0100" MODIFIED_BY="[Empty name]" NAME="Soares-Weiser 2006" TYPE="COCHRANE_REVIEW">
<AU>Soares-Weiser K, Rathbone J</AU>
<TI>Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000459.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Soares_x002d_Weiser-2011" MODIFIED="2016-11-18 13:25:19 +0000" MODIFIED_BY="[Empty name]" NAME="Soares-Weiser 2011" TYPE="COCHRANE_REVIEW">
<AU>Soares-Weiser K, Maayan N, McGrath J</AU>
<TI>Vitamin E for neuroleptic-induced tardive dyskinesia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-11-18 13:25:19 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-11-18 13:25:19 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000209.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tammenmaa-2002" MODIFIED="2016-10-19 07:58:00 +0100" MODIFIED_BY="[Empty name]" NAME="Tammenmaa 2002" TYPE="COCHRANE_REVIEW">
<AU>Tammenmaa I, McGrath J, Sailas E, Soares-Weiser K</AU>
<TI>Cholinergic medication for neuroleptic-induced tardive dyskinesia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000207"/><IDENTIFIER TYPE="MEDLINE" VALUE="22133093"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tarsy-2011" MODIFIED="2017-10-28 22:25:35 +0100" MODIFIED_BY="[Empty name]" NAME="Tarsy 2011" TYPE="JOURNAL_ARTICLE">
<AU>Tarsy D, Lungu C, Baldessarini RJ</AU>
<TI>Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs</TI>
<SO>Handbook of Clinical Neurology / Edited by P.J. Vinken and G.W. Bruyn</SO>
<YR>2011</YR>
<VL>100</VL>
<PG>601-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-2009" MODIFIED="2016-11-27 11:22:38 +0000" MODIFIED_BY="[Empty name]" NAME="Taylor 2009" TYPE="BOOK">
<AU>Taylor D, Paton C, Kapur S</AU>
<SO>The Maudsley Prescribing Guidelines (10th Edition)</SO>
<YR>2009</YR>
<PB>Informa Healthcare</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2016-01-18 10:59:07 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2009" MODIFIED="2016-01-18 10:59:07 +0000" MODIFIED_BY="[Empty name]" NAME="Xia 2009" TYPE="JOURNAL_ARTICLE">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al</AU>
<TI>Loss to outcomes stakeholder survey: the LOSS study</TI>
<SO>Psychiatric Bulletin</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>7</NO>
<PG>254-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-05-25 08:17:04 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Soares_x002d_Weiser-1997" MODIFIED="2017-05-25 08:17:04 +0100" MODIFIED_BY="[Empty name]" NAME="Soares-Weiser 1997" TYPE="COCHRANE_REVIEW">
<AU>Soares-Weiser K, Mobsy C, Holliday E</AU>
<TI>Anticholinergic medication for neuroleptic-induced tardive dyskinesia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-11-18 13:22:06 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-11-18 13:22:06 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000204"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2016-05-22 13:24:15 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES><CHARACTERISTICS_OF_STUDIES MODIFIED="2018-01-17 13:54:16 +0000" MODIFIED_BY="[Empty name]"><CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2018-01-17 13:54:16 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><INCLUDED_CHAR MODIFIED="2017-12-19 13:12:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bucci-1971"><CHAR_METHODS MODIFIED="2016-07-13 09:24:20 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: random, further details not reported.</P><P>Blindness: not reported.</P><P>Duration: 40 weeks.</P><P>Design: parallel.</P><P>Setting: outpatients, USA.</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-12-19 13:12:12 +0000" MODIFIED_BY="[Empty name]"><P>Diagnosis: chronic schizophrenia treated with phenothiazine for several years and demonstrating obvious dyskinetic manifestations.</P><P>Duration of tardive dyskinesia (TD): &#8805;2 years.</P><P>N = 20.</P><P>Sex: 16 female, 4 male.</P><P>Age: range 45 to 62 years.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>1. Procyclidine (anticholinergic), 5 mg B.I.D. + chlorpromazine, 100 mg T.I.D. N = 10.<BR/>2. Isocarboxazid (MAO inhibitor), 10 mg B.I.D. + chlorpromazine, 100 mg T.I.D. N = 10.</P><P>Continuous phenothiazine-antiparkisonian treatment for at least 2 years.</P><P>Other concomitant medication: not reported.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-10-31 15:49:04 +0000" MODIFIED_BY="[Empty name]"><P>TD symptoms: improvement (clinical evaluation, scale not reported).</P><P>Leaving the study early.</P><P>Adverse events.</P><P>Unable to use -</P><UL><LI>Mental state (data not reported for both groups).</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2016-05-29 13:43:18 +0100" MODIFIED_BY="[Empty name]"><P>Sponsorship source: not reported.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-17 13:54:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greil-1984"><CHAR_METHODS MODIFIED="2018-01-17 13:54:16 +0000" MODIFIED_BY="[Empty name]"><P>Allocation: "randomly assigned" no further details.</P><P>Blind: "double-blind" no further details.</P><P>Design: parallel group.</P><P>Setting: not reported if inpatients or outpatients or both; Germany.</P><P>Duration: 7 weeks.</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Diagnosis: chronic schizophrenics (ICD-9) with tardive dyskinesia based on the presence of a 'typical' bucco-linguo-masticatory syndrome and the absence of other adequate explanations for the movement disorder.</P><P>Duration of tardive dyskinesia: &#8805;1 year, severity of the symptoms stable for at least one month before admission to the study.</P><P>N = 10.</P><P>Sex: 7 female, 3 male.</P><P>Age: mean 56.6 (SD 9.2) years; range 35 to 65 years.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-10-28 15:13:10 +0100" MODIFIED_BY="[Empty name]"><P>1. Biperiden (same dose as before the trial) stopped after 4 weeks followed by placebo for 3 weeks. N = 4.</P><P>2. Biperiden (same dose as before the trial) stopped after 1 week followed by placebo for 6 weeks. N = 6.</P><P>All stable on antipsychotics and anticholinergics for at least 5 months before entry and during the trial.</P><P>Other concomitant medication: not reported.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-12-19 13:13:57 +0000" MODIFIED_BY="[Empty name]"><P>Leaving the study early.</P><P>Unable to use (results not reported per randomised group) -</P><UL><LI>TD symptoms: Abnormal Involuntary Movements Scale (AIMS).</LI><LI>EP symptoms: Simpson-Angus Scale.</LI></UL><P>Study author was contacted for additional data but no reply was received.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Sponsorship source: not reported. Knoll AG supplied placebo.<BR/>Declarations of interest: not reported.</P></CHAR_NOTES></INCLUDED_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_INCLUDED_STUDIES><CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2018-01-17 13:48:33 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY"><EXCLUDED_CHAR MODIFIED="2017-05-25 07:56:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casey-1977"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 07:56:22 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: not randomised, controlled clinical study.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 08:02:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DiMascio-1976"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 08:02:03 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: randomised.<BR/>Participants: no TD measure at baseline, not stable dose of antipsychotics.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 08:02:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Double-1993"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 08:02:03 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: randomised.<BR/>Participants: no TD symptoms at baseline.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 07:57:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elie-1972"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 07:57:19 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: randomised.</P><P>Participants: people with chronic schizophrenia, no TD.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 08:02:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fann-1976"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 08:02:03 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: randomised.<BR/>Participants: no TD symptoms at baseline.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-10-31 16:15:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Friis-1983"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-10-31 16:15:53 +0000" MODIFIED_BY="[Empty name]"><P>Allocation: randomised.</P><P>Participants: antipsychotic-induced akathisia, parkinsonism and hyperkinetic movements, 11/15 participants had tardive dyskinesia.<BR/>Intervention: valproate vs biperiden vs placebo.<BR/>Outcomes: two period crossover &#8210; no data about allocation in first period.</P><P>Dr Gerlach (author) contacted and replied promptly. Data were destroyed and no more information is available.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gardos-1984"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: not randomised, controlled clinical trial.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 08:03:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerlach-1976"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 08:03:11 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: not randomised, controlled clinical trial.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 13:48:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerlach-1978"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 13:48:33 +0000" MODIFIED_BY="[Empty name]"><P>Allocation: not randomised - randomisation was only in one arm of the study &#8220;haloperidol + biperiden for 4 weeks (phase 2 and phase 3 in randomized sequence)&#8221;; all other arms were not randomised (thioridazine for 3 months, haloperidol for 4 weeks, thioridazine for 4 weeks, clozapine for 4 weeks).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 08:04:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jus-1974"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 08:04:11 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: not randomised, controlled clinical trial.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klett-1972"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Allocation: randomised.<BR/>Participants: no information about those with TD symptoms at baseline.</P><P>Intervention: benztropine withdrawal vs maintenance.</P><P><BR/>Dr Klett (author) contacted and replied promptly. Data were destroyed and no more information is available.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Konig-1996"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: not randomised, controlled clinical trial.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lejoyeux-1993"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: not randomised, controlled clinical trial.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lieberman-1988"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Allocation: randomised.</P><P>Participants: schizophrenia, schizoaffective disorder, major affective disorder attention deficit disorder and TD (criteria of Schooler &amp; Kane).</P><P>Intervention: physostigmine vs bromocriptine vs benztropine vs haloperidol.</P><P>Outcomes: no outcome data were been provided for the first period before crossover.</P><P>Study author was contacted for data; no additional information was received and as this study is over 25 years old, we excluded this trial.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ludatscher-1989"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Allocation: randomised.<BR/>Participants: people with chronic schizophrenia who had symptoms of severe persistent TD and who had been treated with antipsychotic drugs.</P><P>Intervention: L-dopa 500 mg + carbidopa 50 mg/d + low dose antipsychotics (N = 35) vs placebo + anticholinergic medication + low dose antipsychotic (N = 25).</P><P>Outcomes: no outcome data could be used.</P><P>The study is over 25 years old and we were unable to identify contact details for the author.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NDSG-1986"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Allocation: randomised crossover.<BR/>Participants: psychiatric inpatients with TD.</P><P>Intervention: chlorprothixene vs haloperidol vs perphenazine or haloperidol + biperiden with placebo periods in between phases.</P><P>Outcomes: no outcome data has been provided for the first period before crossover.</P><P>Author was contacted but did not reply. Study is over 30 years old and we excluded it.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-10-31 16:18:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silver-1995"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-10-31 16:18:34 +0000" MODIFIED_BY="[Empty name]"><P>Allocation: randomised.</P><P>Participants: people with schizophrenia (DSM-III-R), with and without TD.</P><P>Interventions: biperiden vs amantadine.</P><P>Outcomes: no outcome data has been provided for the first period before crossover.</P><P>We were unable to find up-to-date contact details for the authors and, as this study is over 20 years old, we excluded this trial.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 08:12:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1979"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 08:12:22 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: not randomised, controlled clinical trial.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tamminga-1977"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: not randomised, ABA design.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wirshing-1989a"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: not randomised, controlled clinical trial.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wirshing-1989b"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: not randomised, controlled clinical trial.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zwanikken-1976"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-25 07:58:11 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: not randomised, controlled clinical trial.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_EXCLUDED_STUDIES><CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><AWAITING_CHAR MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zeng-1996"><CHAR_METHODS MODIFIED="2017-05-25 00:51:41 +0100" MODIFIED_BY="[Empty name]"><P>Allocation: randomised.</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-10-28 15:13:14 +0100" MODIFIED_BY="[Empty name]"><P>Diagnosis: schizophrenia with drug-induced tremor. N = 68.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-10-28 15:13:15 +0100" MODIFIED_BY="[Empty name]"><P>1. Dexetimide. N = 36.<BR/>2. Benzhexol. N = 32.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-05-25 08:13:50 +0100" MODIFIED_BY="[Empty name]"><P>Movement disorder: clinical response.</P><P>Adverse events: TESS.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><P>Language: Chinese &#8210; assessed by Sai Zhao.</P><P>Study authors have been contacted to find out if participants were diagnosed with tardive dyskinesia.</P></CHAR_NOTES></AWAITING_CHAR><FOOTNOTES><P>TESS &#8210; Treatment Emergent Symptom Scale</P></FOOTNOTES></CHARACTERISTICS_OF_AWAITING_STUDIES><CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><FOOTNOTES/></CHARACTERISTICS_OF_ONGOING_STUDIES></CHARACTERISTICS_OF_STUDIES><QUALITY_ITEMS MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-07-13 09:27:31 +0100" MODIFIED_BY="[Empty name]" NO="1"><NAME>Random sequence generation (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-13 09:27:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bucci-1971"><DESCRIPTION><P>&#8220;The patients were divided at random into groups of 10 each&#8221;, no further details reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-31 22:47:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greil-1984"><DESCRIPTION><P>"randomly assigned", further details not reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-05-25 00:50:34 +0100" MODIFIED_BY="[Empty name]" NO="2"><NAME>Allocation concealment (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-25 00:50:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bucci-1971"><DESCRIPTION><P>Allocation concealment not reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-06 00:16:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greil-1984"><DESCRIPTION><P>Allocation concealment not reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3"><NAME>Blinding (performance bias and detection bias)</NAME><DESCRIPTION><P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NO="7"><NAME>Blinding of participants and personnel (performance bias)</NAME><DESCRIPTION><P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-07-13 09:28:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bucci-1971"><DESCRIPTION><P>Blinding of participants and personnel not reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greil-1984"><DESCRIPTION><P>"double-blind" "investigators were not informed about the study design"</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-07-13 09:28:14 +0100" MODIFIED_BY="[Empty name]" NO="8"><NAME>Blinding of outcome assessment (detection bias)</NAME><DESCRIPTION><P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-07-13 09:28:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bucci-1971"><DESCRIPTION><P>Blinding of outcome assessment not reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-31 22:58:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greil-1984"><DESCRIPTION><P>Blinding of raters was not mentioned.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-07-13 09:28:01 +0100" MODIFIED_BY="[Empty name]" NO="4"><NAME>Incomplete outcome data (attrition bias)</NAME><DESCRIPTION><P>Attrition bias due to amount, nature or handling of incomplete outcome data</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-31 23:11:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bucci-1971"><DESCRIPTION><P>&#8220;One male patient on chlorpromazine and isocarboxazid was discontinued after 6 weeks as he became increasingly tense, apprehensive and sleepless.&#8221;</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-05-31 22:46:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greil-1984"><DESCRIPTION><P>"Nine patients completed the trial. One patient dropped out one week after biperiden withdrawal because of severe parkinsonism; in this patient, only one rating could be carried out while on the placebo."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-07-13 09:28:54 +0100" MODIFIED_BY="[Empty name]" NO="5"><NAME>Selective reporting (reporting bias)</NAME><DESCRIPTION><P>Reporting bias due to selective outcome reporting</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-13 09:28:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bucci-1971"><DESCRIPTION><P>Unclear if all outcomes have been reported. A protocol is not available for verification. Adverse effects reported only as those related to treatment. Mental state data not reported for group 2.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-31 22:46:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Greil-1984"><DESCRIPTION><P>TD symptoms data were not reported per randomised group, but before biperiden removal versus after biperiden removal.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-05-25 00:50:39 +0100" MODIFIED_BY="[Empty name]" NO="6"><NAME>Other bias</NAME><DESCRIPTION><P>Bias due to problems not covered elsewhere in the table</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-25 00:50:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bucci-1971"><DESCRIPTION><P>Insufficient information to make a judgement.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-06 00:17:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greil-1984"><DESCRIPTION><P>Insufficient information to make a judgement.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM></QUALITY_ITEMS><SOF_TABLES MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><SOF_TABLE ID="SOF-01" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NO="1"><TITLE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]">Anticholinergic medication compared with placebo for antipsychotic-induced tardive dyskinesia</TITLE><TABLE COLS="7" ROWS="13"><TR><TD COLSPAN="7"><P><B>Anticholinergic medication</B><B> compared with other treatments for antipsychotic-induced tardive dyskinesia</B></P></TD></TR><TR><TD COLSPAN="7"><P><B>Patient or population:</B> patients with antipsychotic-induced tardive dyskinesia</P><P><B>Settings: </B>anywhere.</P><P><B>Intervention: </B>any anticholinergic</P><P><B>Comparison: </B>placebo</P></TD></TR><TR><TH ROWSPAN="3" VALIGN="TOP"><P>Outcomes</P></TH><TH COLSPAN="2" VALIGN="TOP"><P>Illustrative comparative risks* (CI)</P></TH><TH ROWSPAN="3" VALIGN="TOP"><P>Relative effect<BR/>(CI)</P></TH><TH ROWSPAN="3" VALIGN="TOP"><P>No of Participants<BR/>(studies)</P></TH><TH ROWSPAN="3" VALIGN="TOP"><P>Quality of the evidence<BR/>(GRADE)</P></TH><TH ROWSPAN="3" VALIGN="TOP"><P>Comments</P></TH></TR><TR><TH VALIGN="TOP"><P>Assumed risk</P></TH><TH VALIGN="TOP"><P>Corresponding risk</P></TH></TR><TR><TH VALIGN="TOP"><P>risk with placebo</P></TH><TH VALIGN="TOP"><P>risk with anticholinergic drugs</P></TH></TR><TR><TD VALIGN="TOP"><P><B>Tardive dyskinesia: not improved to a clinically important extent</B></P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>not estimable</P></TD><TD VALIGN="TOP"><P>(0 studies)</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD VALIGN="TOP"><P><B>Tardive dyskinesia: deterioration of symptoms</B></P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>not estimable</P></TD><TD VALIGN="TOP"><P>(0 studies)</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD VALIGN="TOP"><P><B>Mental state</B></P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>not estimable</P></TD><TD VALIGN="TOP"><P>(0 studies)</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD VALIGN="TOP"><P><B>Adverse effect: any adverse effects</B><BR/>follow-up: 40 weeks</P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>not estimable</P></TD><TD VALIGN="TOP"><P>(0 studies)</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD VALIGN="TOP"><P><B>Acceptability of the treatment: leaving the study early</B></P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>not estimable</P></TD><TD VALIGN="TOP"><P>(0 studies)</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD VALIGN="TOP"><P><B>Social confidence, social inclusion, social networks, or personalised quality of life</B></P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>not estimable</P></TD><TD VALIGN="TOP"><P>(0 studies)</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD COLSPAN="7"><P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its CI).<BR/><B>CI:</B> Confidence interval; <B>MAO</B>: monoamine oxidase; <B>RR:</B> Risk Ratio</P></TD></TR><TR><TD COLSPAN="7"><P>GRADE Working Group grades of evidence<BR/><B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/><B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/><B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/><B>Very low quality:</B> We are very uncertain about the estimate.</P></TD></TR></TABLE><FOOTNOTES><P><SUP>1</SUP> Downgraded one level for risk of bias: the included study did not adequately describe randomisation procedure or allocation concealment, and there was no mention of the study being blinded.</P><P><SUP>2</SUP> Downgraded two levels for imprecision: very small sample size (n = 20).</P><P><SUP>3</SUP> Downgraded two levels for imprecision: very wide CI that includes appreciable benefit for both groups; very small sample size (n = 20).</P><P><SUP>4</SUP> Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability.</P></FOOTNOTES></SOF_TABLE><SOF_TABLE ID="SOF-02" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NO="2"><TITLE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]">Anticholinergic medication compared with other treatments for antipsychotic-induced tardive dyskinesia</TITLE><TABLE COLS="7" ROWS="13"><TR><TD COLSPAN="7"><P><B>Anticholinergic medication compared with other treatments for antipsychotic-induced tardive dyskiesia</B></P></TD></TR><TR><TD COLSPAN="7"><P><B>Patient or population: </B>chronic schizophrenia patients with antipsychotic-induced tardive dyskinesia</P><P><B>Settings: </B>outpatients in the USA.</P><P><B>Intervention: </B>procyclidine (anticholinergic), 5 mg twice/day</P><P><B>Comparison: </B>isocarboxazid (MAO-inhibitor), 10 mg twice/day</P></TD></TR><TR><TH ROWSPAN="3" VALIGN="TOP"><P>Outcomes</P></TH><TH COLSPAN="2" VALIGN="TOP"><P>Illustrative comparative risks* (CI)</P></TH><TH ROWSPAN="3" VALIGN="TOP"><P>Relative effect<BR/>(CI)</P></TH><TH ROWSPAN="3" VALIGN="TOP"><P>No of Participants<BR/>(studies)</P></TH><TH ROWSPAN="3" VALIGN="TOP"><P>Quality of the evidence<BR/>(GRADE)</P></TH><TH ROWSPAN="3" VALIGN="TOP"><P>Comments</P></TH></TR><TR><TH VALIGN="TOP"><P>Assumed risk</P></TH><TH VALIGN="TOP"><P>Corresponding risk</P></TH></TR><TR><TH VALIGN="TOP"><P>risk with MAO-inhibitor</P></TH><TH VALIGN="TOP"><P>risk with anticholinergic drugs</P></TH></TR><TR><TD VALIGN="TOP"><P><B>Tardive dyskinesia: Not improved to a clinically important extent</B><BR/>follow-up: 40 weeks</P></TD><TD VALIGN="TOP"><P><B>200 per 1000</B></P></TD><TD VALIGN="TOP"><P><B>840 per 1000</B><BR/>(280 to 1000)</P></TD><TD VALIGN="TOP"><P><B>RR 4.20</B> (1.40 to 12.58)</P></TD><TD VALIGN="TOP"><P>20<BR/>(1 study)</P></TD><TD VALIGN="TOP"><P>&#8853;&#8861;&#8861;&#8861;<BR/><B>very low</B><SUP>1 2</SUP></P></TD><TD VALIGN="TOP"><P/></TD></TR><TR><TD VALIGN="TOP"><P><B>Tardive dyskinesia: deterioration of symptoms</B></P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>not estimable</P></TD><TD VALIGN="TOP"><P>(0 studies)</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD VALIGN="TOP"><P><B>Mental state</B></P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>not estimable</P></TD><TD VALIGN="TOP"><P>(0 studies)</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD VALIGN="TOP"><P><B>Adverse effect: any adverse effects</B><BR/>follow-up: 40 weeks</P></TD><TD VALIGN="TOP"><P><B>100 per 1000</B></P></TD><TD VALIGN="TOP"><P><B>33 per 1000</B><BR/>(2 to 732)</P></TD><TD VALIGN="TOP"><P><B>RR 0.33</B> (0.02 to 7.32)</P></TD><TD VALIGN="TOP"><P>20<BR/>(1 study)</P></TD><TD VALIGN="TOP"><P>&#8853;&#8861;&#8861;&#8861;<BR/><B>very low</B><SUP>1 3</SUP><BR/></P></TD><TD VALIGN="TOP"><P/></TD></TR><TR><TD VALIGN="TOP"><P><B>Acceptability of the treatment: leaving the study early</B><BR/>follow-up: 40 weeks</P></TD><TD VALIGN="TOP"><P><B>100 per 1000</B></P></TD><TD VALIGN="TOP"><P><B>33 per 1000</B><BR/>(2 to 732)</P></TD><TD VALIGN="TOP"><P><B>RR 0.33</B> (0.02 to 7.32)</P></TD><TD VALIGN="TOP"><P>20<BR/>(1 study)</P></TD><TD VALIGN="TOP"><P>&#8853;&#8861;&#8861;&#8861;<BR/><B>very low</B><SUP>1 3 4</SUP></P></TD><TD VALIGN="TOP"><P/></TD></TR><TR><TD VALIGN="TOP"><P><B>Social confidence, social inclusion, social networks, or personalised quality of life</B></P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>see comment</P></TD><TD VALIGN="TOP"><P>not estimable</P></TD><TD VALIGN="TOP"><P>(0 studies)</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD COLSPAN="7"><P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its CI).<BR/><B>CI:</B> Confidence interval; <B>MAO</B>: monoamine oxidase; <B>RR:</B> Risk Ratio</P></TD></TR><TR><TD COLSPAN="7"><P>GRADE Working Group grades of evidence<BR/><B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/><B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/><B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/><B>Very low quality:</B> We are very uncertain about the estimate.</P></TD></TR></TABLE><FOOTNOTES><P><SUP>1</SUP> Downgraded one level for risk of bias: the included study did not adequately describe randomisation procedure or allocation concealment, and there was no mention of the study being blinded.</P><P><SUP>2</SUP> Downgraded two levels for imprecision: very small sample size (n = 20).</P><P><SUP>3</SUP> Downgraded two levels for imprecision: very wide CI that includes appreciable benefit for both groups; very small sample size (n = 20).</P><P><SUP>4</SUP> Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability.</P></FOOTNOTES></SOF_TABLE><SOF_TABLE ID="SOF-03" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES"><TITLE MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]">Withdrawal of anticholinergic medication compared to continuing anticholinergic medication for antipsychotic-induced tardive dyskinesia</TITLE><TABLE COLS="7" ROWS="12"><TR><TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP"><P><B>Withdrawal of anticholinergic medication compared to continuing anticholigergic medication for antipsychotic-induced tardive dyskinesia</B></P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP"><P><B>Patient or population: </B>chronic schizophrenia patients with antipsychotic-induced tardive dyskinesia<BR/><B>Setting: </B>Germany (1 study)<BR/><B>Intervention: </B>withdrawal of biperiden (stopping after 1 week)<BR/><B>Comparison: </B>continuing biperiden (stopping after 4 weeks)</P></TD></TR><TR><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Outcomes</P></TH><TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Anticipated absolute effects<SUP>*</SUP> (CI)</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Relative effect<BR/>(CI)</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>&#8470; of participants<BR/>(studies)</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Quality of the evidence<BR/>(GRADE)</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Comments</P></TH></TR><TR><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>Risk with continuation of anticholinergic drugs</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>Risk with withdrawal of anticholinergic drugs</P></TH></TR><TR><TD><P><B>Tardive dyskinesia: not improved to a clinically important extent</B></P></TD><TD><P>see comment</P></TD><TD><P>see comment</P></TD><TD><P>not estimable</P></TD><TD><P>0</P><P>(0 studies)</P></TD><TD><P>-</P></TD><TD><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD><P><B>Tardive dyskinesia: deterioration of symptoms</B></P></TD><TD><P>see comment</P></TD><TD><P>see comment</P></TD><TD><P>not estimable</P></TD><TD><P>0</P><P>(0 studies)</P></TD><TD><P>-</P></TD><TD><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD><P><B>Mental state</B></P></TD><TD><P>see comment</P></TD><TD><P>see comment</P></TD><TD><P>not estimable</P></TD><TD><P>0</P><P>(0 studies)</P></TD><TD><P>-</P></TD><TD><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD><P><B>Adverse effects</B></P></TD><TD><P>see comment</P></TD><TD><P>see comment</P></TD><TD><P>not estimable</P></TD><TD><P>0</P><P>(0 studies)</P></TD><TD><P>-</P></TD><TD><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P><B>Acceptability of the treatment: leaving the study early</B><BR/>follow-up: 7 weeks</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P><B>0 per 1,000</B></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P><B>0 per 1,000</B><BR/>(0 to 0)</P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P>RR 2.14<BR/>(0.11 to 42.52)</P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P>10<BR/>(1 RCT)</P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P>&#8853;&#8861;&#8861;&#8861;<BR/><B>very low</B> <SUP>1 2 3</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP"><P/></TD></TR><TR><TD><P><B>Social confidence, social inclusion, social networks, or personalised quality of life</B></P></TD><TD><P>see comment</P></TD><TD><P>see comment</P></TD><TD><P>not estimable</P></TD><TD><P>0</P><P>(0 studies)</P></TD><TD><P>-</P></TD><TD><P>None of the included studies reported on this outcome.</P></TD></TR><TR><TD COLSPAN="7"><P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its CI).<BR/><BR/><B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P></TD></TR><TR><TD COLSPAN="7"><P><B>GRADE Working Group grades of evidence</B><BR/><B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/><B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/><B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/><B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P></TD></TR></TABLE><FOOTNOTES><P><SUP>1</SUP> Downgraded one level for risk of bias: the included study did not adequately describe randomisation procedure or allocation concealment.</P><P><SUP>2</SUP> Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. In addition, the continuation of anticholinergic medication group stopped biperiden after 4 weeks but the results were measured after 7 weeks.</P><P><SUP>3</SUP> Downgraded two levels for imprecision: very wide CI that includes appreciable benefit for both groups; very small sample size (n = 10).</P></FOOTNOTES></SOF_TABLE></SOF_TABLES><ADDITIONAL_TABLES MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2017-10-04 13:22:39 +0100" MODIFIED_BY="[Empty name]" NO="1"><TITLE MODIFIED="2016-10-14 12:26:35 +0100" MODIFIED_BY="[Empty name]">Other reviews in the series</TITLE><TABLE COLS="2" ROWS="10"><TR><TD><P><B>Interventions</B></P></TD><TD><P><B>Reference</B></P></TD></TR><TR><TD><P>Anticholinergic medication</P></TD><TD><P>This review</P></TD></TR><TR><TD><P>Benzodiazepines</P></TD><TD><P><LINK REF="REF-Bhoopathi-2006" TYPE="REFERENCE">Bhoopathi 2006</LINK>; update to be published</P></TD></TR><TR><TD><P>Calcium channel blockers</P></TD><TD><P><LINK REF="REF-Essali-2011" TYPE="REFERENCE">Essali 2011</LINK>; update to be published</P></TD></TR><TR><TD><P>Cholinergic medication</P></TD><TD><P><LINK REF="REF-Tammenmaa-2002" TYPE="REFERENCE">Tammenmaa 2002</LINK>; update to be published</P></TD></TR><TR><TD><P>Gamma-aminobutyric acid agonists</P></TD><TD><P><LINK REF="REF-Alabed-2011" TYPE="REFERENCE">Alabed 2011</LINK>; update to be published</P></TD></TR><TR><TD><P>Miscellaneous treatments</P></TD><TD><P><LINK REF="REF-Soares_x002d_Weiser-2003" TYPE="REFERENCE">Soares-Weiser 2003</LINK>; update to be published</P></TD></TR><TR><TD><P>Neuroleptic reduction and/or cessation and neuroleptics</P></TD><TD><P><LINK REF="REF-Soares_x002d_Weiser-2006" TYPE="REFERENCE">Soares-Weiser 2006</LINK>; update to be published</P></TD></TR><TR><TD><P>Non-neuroleptic catecholaminergic drugs</P></TD><TD><P><LINK REF="REF-El_x002d_Sayeh-2006" TYPE="REFERENCE">El-Sayeh 2006</LINK>; update to be published</P></TD></TR><TR><TD><P>Vitamin E</P></TD><TD><P><LINK REF="REF-Soares_x002d_Weiser-2011" TYPE="REFERENCE">Soares-Weiser 2011</LINK>; update to be published</P></TD></TR></TABLE><FOOTNOTES/></ADDITIONAL_TABLE><ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NO="2"><TITLE MODIFIED="2016-11-21 07:47:35 +0000" MODIFIED_BY="[Empty name]">Suggestions for design of future study</TITLE><TABLE COLS="2" ROWS="5"><TR><TH><P>Methods</P></TH><TD><P>Allocation: randomised, with sequence generation and concealment of allocation clearly described.<BR/>Blindness: double, tested.<BR/>Duration: 12 months beyond end of intervention at least.<BR/>Raters: independent.</P></TD></TR><TR><TH><P>Participants</P></TH><TD><P>People with antipsychotic-induced tardive dyskinesia.*<BR/>Age: any.<BR/>Sex: both.<BR/>History: any.<BR/>N = 300.**<BR/></P></TD></TR><TR><TH><P>Interventions</P></TH><TD><P>1. Anticholinergic withdrawal (N = 150) versus anticholinergic continuation (N = 150).</P><P>OR</P><P>2. Specific anticholinergic (N = 150) versus placebo (N = 150).</P></TD></TR><TR><TH><P>Outcomes</P></TH><TD><P>Tardive dyskinesia: any clinically important improvement in TD, any improvement, deterioration.***<BR/>Adverse effects: no clinically significant extrapyramidal adverse effects &#8210; any time period***, use of any antiparkinsonism drugs, other important adverse events.<BR/>Leaving the study early.<BR/>Service outcomes: admitted, number of admissions, length of hospitalisation, contacts with psychiatric services.<BR/>Compliance with drugs.<BR/>Economic evaluations: cost-effectiveness, cost-benefit.<BR/>General state: relapse, frequency and intensity of minor and major exacerbations.<BR/>Social confidence, social inclusion, social networks, or personalised quality of life: binary measure<BR/>Distress among relatives: binary measure.<BR/>Burden on family: binary measure.<BR/></P></TD></TR><TR><TH><P>Notes</P></TH><TD><P>* This could be diagnosed by clinical decision. If funds were permitting, all participants could be screened using operational criteria; otherwise a random sample should suffice.</P><P>** Size of study with sufficient power to highlight about a 10% difference between groups for primary outcome.<BR/>*** Primary outcome. The same applies to the measure of primary outcome as for diagnosis. Not everyone may need to have operational criteria applied if clinical impression is proved to be accurate.<BR/></P></TD></TR></TABLE><FOOTNOTES/></ADDITIONAL_TABLE></ADDITIONAL_TABLES><ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]"><COMPARISON ID="CMP-001" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NO="1"><NAME>Anticholinergic medications versus other compounds</NAME><DICH_OUTCOME CHI2="0.0" CI_END="12.583031067983816" CI_START="1.4018879795094135" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.099785268894548" LOG_CI_START="0.1467133119012532" LOG_EFFECT_SIZE="0.6232492903979004" METHOD="IV" MODIFIED="2017-06-26 08:13:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.010365641774695037" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="2.563387063498763"><NAME>TD symptoms: no clinically significant improvement</NAME><GROUP_LABEL_1>Procyclidine</GROUP_LABEL_1><GROUP_LABEL_2>Isocarboxazid</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Procyclidine</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Isocarboxazid</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="12.583031067983816" CI_START="1.4018879795094135" DF="0" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="1.099785268894548" LOG_CI_START="0.1467133119012532" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2017-06-26 08:13:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.010365641774695037" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="2.563387063498763"><NAME>procyclidine vs isocarboxazid</NAME><DICH_DATA CI_END="12.583031067983816" CI_START="1.4018879795094135" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.099785268894548" LOG_CI_START="0.1467133119012532" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2016-07-14 14:00:25 +0100" MODIFIED_BY="[Empty name]" ORDER="822" O_E="0.0" SE="0.5598391853201358" STUDY_ID="STD-Bucci-1971" TOTAL_1="10" TOTAL_2="10" VAR="0.3134199134199134" WEIGHT="100.0"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0" CI_END="31.145994658105273" CI_START="1.5732359983324042" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.4934022047760227" LOG_CI_START="0.1967938752524908" LOG_EFFECT_SIZE="0.8450980400142568" METHOD="IV" MODIFIED="2017-06-26 08:13:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.010621387906631287" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="2.5549145167716154"><NAME>TD symptoms: not any improvement</NAME><GROUP_LABEL_1>Procyclidine</GROUP_LABEL_1><GROUP_LABEL_2>Isocarboxazid</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Procyclidine</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Isocarboxazid</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="31.145994658105273" CI_START="1.5732359983324042" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="1.4934022047760227" LOG_CI_START="0.1967938752524908" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2017-06-26 08:13:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.010621387906631287" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="2.5549145167716154"><NAME>procyclidine vs isocarboxazid</NAME><DICH_DATA CI_END="31.145994658105273" CI_START="1.5732359983324042" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.4934022047760227" LOG_CI_START="0.1967938752524908" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2016-06-27 13:16:24 +0100" MODIFIED_BY="[Empty name]" ORDER="821" O_E="0.0" SE="0.761634151076867" STUDY_ID="STD-Bucci-1971" TOTAL_1="10" TOTAL_2="10" VAR="0.58008658008658" WEIGHT="100.0"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0" CI_END="7.3225436971144395" CI_START="0.015173840636129785" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="IV" MODIFIED="2017-06-26 08:13:27 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.48584124712227683" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.6969385642065118"><NAME>Adverse effects</NAME><GROUP_LABEL_1>Procyclidine</GROUP_LABEL_1><GROUP_LABEL_2>Isocarboxazid</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Procyclidine</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Isocarboxazid</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="7.3225436971144395" CI_START="0.015173840636129785" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2017-06-26 08:13:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.48584124712227683" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.6969385642065118"><NAME>procyclidine vs isocarboxazid</NAME><DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2016-05-31 23:12:23 +0100" MODIFIED_BY="[Empty name]" ORDER="820" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Bucci-1971" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="100.0"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0" CI_END="7.3225436971144395" CI_START="0.015173840636129785" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="IV" MODIFIED="2017-06-26 08:13:19 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.48584124712227683" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.6969385642065118"><NAME>Leaving the study early</NAME><GROUP_LABEL_1>Procyclidine</GROUP_LABEL_1><GROUP_LABEL_2>Isocarboxazid</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Procyclidine</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Isocarboxazid</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="7.3225436971144395" CI_START="0.015173840636129785" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2017-06-26 08:13:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.48584124712227683" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.6969385642065118"><NAME>procyclidine vs isocarboxazid</NAME><DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2016-05-31 23:12:23 +0100" MODIFIED_BY="[Empty name]" ORDER="820" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Bucci-1971" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="100.0"/></DICH_SUBGROUP></DICH_OUTCOME></COMPARISON><COMPARISON ID="CMP-002" MODIFIED="2017-12-19 13:09:03 +0000" MODIFIED_BY="[Empty name]" NO="2"><NAME>Continuation versus withdrawal of anticholinergic medications</NAME><DICH_OUTCOME CHI2="0.0" CI_END="42.5176062762688" CI_START="0.10799847726274302" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.6285688059389567" LOG_CI_START="-0.966582367856108" LOG_EFFECT_SIZE="0.3309932190414244" METHOD="IV" MODIFIED="2017-06-26 08:13:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6171038428250735" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6" TOTAL_2="4" WEIGHT="100.0" Z="0.499959150741481"><NAME>Leaving the study early</NAME><GROUP_LABEL_1>1 week Biperiden</GROUP_LABEL_1><GROUP_LABEL_2>4 week Biperiden</GROUP_LABEL_2><GRAPH_LABEL_1>Favours 1 week Biperiden</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours 4 week Biperiden</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="42.5176062762688" CI_START="0.10799847726274302" DF="0" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="1.6285688059389567" LOG_CI_START="-0.966582367856108" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2017-06-26 08:13:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6171038428250735" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="4" WEIGHT="100.0" Z="0.499959150741481"><NAME>biperiden: withdrawal after 1 week vs withdrawal after 4 weeks</NAME><DICH_DATA CI_END="42.5176062762688" CI_START="0.10799847726274302" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6285688059389567" LOG_CI_START="-0.966582367856108" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2016-06-27 13:05:10 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="1.5244046456927123" STUDY_ID="STD-Greil-1984" TOTAL_1="6" TOTAL_2="4" VAR="2.3238095238095235" WEIGHT="100.0"/></DICH_SUBGROUP></DICH_OUTCOME></COMPARISON></ANALYSES_AND_DATA><FIGURES MODIFIED="2017-12-19 13:09:07 +0000" MODIFIED_BY="[Empty name]"><FIGURE FILENAME="TD it's about time!!!.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2016-06-27 13:07:16 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Message from one of the participants of the Public and patient involvement consultation of service user perspectives on tardive dyskinesia research.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-12-19 13:09:07 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT"><CAPTION><P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-12-19 13:09:07 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT"><CAPTION><P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2017-10-11 14:15:29 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Study flow diagram for 2015 and 2017 searches.</P></CAPTION><FILE>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</FILE></FIGURE></FIGURES><FEEDBACK><FEEDBACK_ITEM ID="FBK-01" NO="1"><TITLE>Crossover studies</TITLE><DATE_SUBMITTED><DATE DAY="" MONTH="" YEAR=""/></DATE_SUBMITTED><FEEDBACK_SUMMARY><P>Category: Methods <BR/>A general comment regarding the use and interpretation of data obtained from crossover studies. The statistical questions remain unanswered and thus only data from the first treatment period can legitimately be used. However this data is rarely presented in reports of such trials leading to their exclusion from the systematic review. The author of the comment mentions that the chronic and unstable nature of TD should not disfavour a crossover trial design as suggested by the reviewers. The review would be enhanced if the authors made some recommendations on the characteristics of a crossover study that would allow its inclusion in a systematic review such as this one.</P></FEEDBACK_SUMMARY><FEEDBACK_REPLY><P>In the TD reviews data were pooled from the first period where it was possible to do so. When impossible the results were reported without pooling. Most of the crossover trials lasted less than six weeks. Recently we have analysed data from studies using placebo and found 37.3% improved their TD symptoms. We suggest that future RCTs investigating the treatment of TD should utilise a parallel group design.</P></FEEDBACK_REPLY><FEEDBACK_CONTRIBUTORS><P>Comment received from Jon Deeks, Oxford, UK, August 1997.<BR/>Reply from Karla Soares, Barcelona, Spain, December 1997.</P></FEEDBACK_CONTRIBUTORS></FEEDBACK_ITEM></FEEDBACK><APPENDICES MODIFIED="2017-12-19 13:08:50 +0000" MODIFIED_BY="[Empty name]"><APPENDIX ID="APP-01" MODIFIED="2017-12-19 13:08:50 +0000" MODIFIED_BY="[Empty name]" NO="1"><TITLE MODIFIED="2016-11-18 13:01:51 +0000" MODIFIED_BY="[Empty name]">Previous methods and searches</TITLE><APPENDIX_BODY MODIFIED="2017-12-19 13:08:50 +0000" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="3">Criteria for considering studies for this review</HEADING></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Types of studies</HEADING><P>We attempted to identify all relevant randomized controlled trials.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Types of participants</HEADING><P>People with schizophrenia or schizoaffective disorder or any other chronic mental illnesses, diagnosed by any criteria, irrespective of gender, age or nationality who;<BR/>i. required the use of neuroleptics for more than three months;<BR/>ii. developed tardive dyskinesia (diagnosed by any criteria at baseline and at least one other occasion) during neuroleptic treatment; and<BR/>iii. for whom the dose of neuroleptic medication had been stable for one month or more (the same applies for those free of neuroleptics).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Types of interventions</HEADING><P>i. Anticholinergic drugs (benzhexol, benztropine, biperiden, dexetimide, orphenadrine, procyclidine, scopolamine, trihexylphenidyl) compared to placebo, or no intervention; or<BR/>ii. the withdrawal of the above anticholinergic drugs compared with the continuation of the treatment.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Types of outcome measures</HEADING><P>Clinical efficacy was defined as an improvement in the symptoms of TD of more than 50%, on any scale, after at least six weeks of intervention.</P><P>The outcomes of interest were:</P><P>A. Tardive dyskinesia changes<BR/>i. The number of people per treatment group that did not show an improvement in the symptoms of individuals of more than 50% on any TD scale;<BR/>ii. the number of people per treatment group that did not show any improvement in the symptoms of individuals on any TD scale, as opposed to some improvement;<BR/>iii. deterioration in the symptoms of individuals, defined as any deleterious change on any TD scale;<BR/>iv. any adverse effect, other than deterioration of symptoms of TD, as reported in the trials;<BR/>v. average change in severity of TD during the trial period; and<BR/>vi. average difference in severity of TD at the end of the trial.</P><P>B. General mental state changes<BR/>i. Deterioration in general psychiatric symptoms (such as delusions and hallucinations) defined as any deleterious change on any scale; and<BR/>ii. average difference in severity of psychiatric symptoms at the end of the trial.</P><P>C. Acceptability of the treatment<BR/>Acceptability of the intervention to the participant group as measured by numbers of people dropping out during the trial.</P><P>When feasible, the outcomes were grouped into time periods - short term (less than 6 weeks), medium term (between 6 weeks and 6 months) and long term (over 6 months).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Search methods for identification of studies</HEADING><P>1. Electronic searching<BR/>Relevant randomized trials were identified by searching the following electronic databases:</P><P>1.1 Biological Abstracts on Silverplatter WinSPIRS 4.0 (January 1982 to March 2000) was searched using the Cochrane Schizophrenia Group's phrase for randomized controlled trials (see Group search strategy) combined with:</P><P>[AND (tardive near (dyskine* or diskine*)) or (abnormal near movement* near disorder*) or (involuntar* near movement*))]</P><P>This downloaded set of reports was handsearched for possible trials and researched, within the bibliographic package ProCite, with the phrase [anticholinergic* or antiparkinsonian* or benzhexol or benztropine or biperiden or dexetimide or orphenadrine or procyclidine or scopolamine or trihexyphenidyl]</P><P>1.2 CINAHL on Silverplatter WinSPIRS 4.0 (1982 - April 2000) was searched using the Cochrane Schizophrenia Group's phrase for randomized controlled trials (see Group search strategy) combined with:</P><P>[AND (explode "Movement-Disorders"/ all topical subheadings / all age subheadings) or (explode "Movement-Disorders"/ all topical subheadings / all age subheadings) or (tardive near (dyskine* or diskine*)) or (abnormal* near movement* near disorder*) or (involuntar* near movement*)</P><P>This downloaded set of reports was handsearched for possible trials and researched, within the bibliographic package ProCite, with the phrase [anticholinergic* or antiparkinsonian* or benzhexol or benztropine or biperiden or dexetimide or orphenadrine or procyclidine or scopolamine or trihexyphenidyl]</P><P>1.3 CCTR/CENTRAL of the Cochrane Library (Issue 2, 2000) was searched using the phrase:</P><P>[((movement-disorders*:me) or (dyskinesia-drug-induced:me) or (anti-dyskinesia-agents*:me) or (tardive near (dyskine* or dyskine*)) or (neuroleptic near dyskine*) or (abnormal* near movement* near disorder*) or (involuntar* near movement*)) and<BR/>(anticholinergic* or antiparkinsonian* or benzhexol* or benztroprine or biperiden or dexetimide or orphenadrine or procyclidine or scopolamine or trihexyphenidyl)]</P><P>1.4 Cochrane Schizophrenia Group's Register was searched using the phrase:</P><P>[anticholinergic* or antiparkinsonian* or benzhexol or benztropine or biperiden or dexetimide or orphenadrine or procyclidine or scopolamine or trihexylphenidyl]</P><P>1.5 EMBASE on Silverplatter WinSPIRS 4.0 (January 1980 to May 2000) was searched using the Cochrane Schizophrenia Group's phrase for randomized controlled trials (see Group search strategy) combined with:</P><P>[AND (("tardive-dyskinesia"/ all subheadings) or ("dyskinesia"/ all subheadings) or ("motor dysfunction"/ all subheadings) or (tardive near (dyskines* or diskines*)) or (abnormal* near movement* near disorder*) or involuntar* near movement*))]</P><P>This downloaded set of reports was handsearched for possible trials and researched, within the bibliographic package ProCite, with the phrase [anticholinergic* or antiparkinsonian* or benzhexol or benztropine or biperiden or dexetimide or orphenadrine or procyclidine or scopolamine or trihexyphenidyl]</P><P>1.6 LILACS (January 1982 to September 1996) was searched using the CSG's phrase for randomized controlled trials (see Group search strategy) combined with the phrase:</P><P>[AND ((tardive or (dyskinesia* or diskinesia*)) or (drug induced movement disorders in thesaurus))]</P><P>This downloaded set of reports was handsearched for possible trials and researched, within the bibliographic package ProCite, with the phrase [anticholinergic* or antiparkinsonian* or benzhexol or benztropine or biperiden or dexetimide or orphenadrine or procyclidine or scopolamine or trihexylphenidyl]</P><P>1.7 MEDLINE on Silverplatter WinSPIRS 4.0 (January 1966 to June 2000) was searched using the Cochrane Schizophrenia Group's phrase for randomized controlled trials (see Group search strategy) combined with:</P><P>[AND ((explode "movement-disorders" in MeSH / all subheadings) or (explode "anti-dyskinesia-agents" in MeSH / all subheadings) or (explode "dyskinesia-drug-induced" in MeSH / all subheadings) and<BR/>(explode "psychotic-disorders" in MeSH / all subheadings) or (explode "schizophrenic disorders" in MeSH / all subheadings) or (tardive near (dyskine* or diskine*)) or (abnormal* near movement* near disorder*) or (involuntar* near movement*))]</P><P>This downloaded set of reports was handsearched for possible trials and researched, within the bibliographic package ProCite, with the phrase [anticholinergic* or antiparkinsonian* or benzhexol or benztropine or biperiden or dexetimide or orphenadrine or procyclidine or scopolamine or trihexyphenidyl]</P><P>1.8 PsycLIT on Silverplatter WinSPIRS 4.0 (January 1974 to March 2000) was searched using the Cochrane Schizophrenia Group's phrase for randomized controlled trials (see Group search strategy) combined with the phrase:</P><P>[AND ((explode "movement-disorders") or ("tardive-dyskinesia" in DE) or (tardive near (dyskine* or diskine*)) or (abnormal* near movement* near disorder*) or (involuntar* near movement*))]</P><P>This downloaded set of reports was handsearched for possible trials and researched, within the bibliographic package ProCite, with the phrase [anticholinergic* or antiparkinsonian* or benzhexol or benztropine or biperiden or dexetimide or orphenadrine or procyclidine or scopolamine or trihexyphenidyl]</P><P>1.9 SCISEARCH - Science Citation Index<BR/>Each of the included studies was sought as a citation on the SCISEARCH database. Reports of articles that had cited these studies were inspected in order to identify further trials.</P><P>1.10 Cochrane Schizophrenia Group Trials Register</P><P>The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group&#8217;s Trials Register (November 11, 2013)</P><P>[((*Akineton* or *Anticholinergic* or *Antimuscarinic* or *Aparkan* or *Arpicolin* or *Artane* or *Atropine* or *Banflex* or *Benapr* or *Benzatropine* or *Benzhexol* or *Benztropine* or *Biperiden* or *Biorphen* or *Bornaprine* or *Broflex* or *Buscopan or *Cholinergic* or *Cogentin* or *Cycrimine* or *Darifenacin* or *Dicycloverine* or *Diphenhydramine* or *Disipal* or *Elantrine* Or *Ethopropazine* or *Flavoxate* or *Flexon* or *Hyoscine* or *Kemadrin* or *Mephenamin* or *Muscarinic* or *Norflex* or *Oxybutynin* or *Parkin* or *Parsid* or *Orphenadrine* or *Pro-banthine* or *Procyclidine* or *Profenamine* or *Propantheline* or *Propiverine* or *Scopolamine* or *Solifenacin* or *Tolterodine* or *Trihexyphenidyl* or *Trospium*) in title abstract or index terms of REFERENCE)) and ((*dyskinesia* in title abstract or index terms of REFERENCE) and (Tardive dyskinesia in health care conditions of STUDY))]</P><P>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches of journals and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). Incoming trials are assigned to existing or new review titles.</P><P>2. Reference searching<BR/>The references of all identified studies were also inspected for more studies.</P><P>3. Personal contact<BR/>The first author of each included study was contacted for information regarding unpublished trials.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Data collection and analysis</HEADING><P>[For definitions of terms used in this, and other sections, please refer to the Glossary.]</P><P>The abstract of each reference identified by the search was inspected, independently, by both reviewers, to see if the study was likely to be relevant. For articles that could possible have been RCTs, or in cases of disagreement between the two reviewers, the full article was obtained. In turn, these articles were then inspected, independently, to assess their relevance to this review. Again, where resolving disagreement by discussion was not possible, the article was added to those awaiting assessment and the authors of the study were contacted for clarification.</P><P>The reviewers independently evaluated the quality of all included trials. A rating was given for each trial based on the three quality categories as described in the Cochrane Collaboration Handbook (<LINK REF="REF-Mulrow-1999" TYPE="REFERENCE">Mulrow 1999</LINK>). Only trials stated to be randomized (category A or B of the Handbook) were included in this review.</P><P>Data were independently extracted by both reviewers. Again, any disagreement was discussed, the decisions documented and, where necessary, the authors of the studies were contacted for clarification. Justification for excluding references from the review was documented. If insufficient information could be extracted from the publication, a letter was sent to the first author for further clarification. There references were allocated to the 'Awaiting assessment' list. In the absence of specific details, the reviewers assumed that subjects dropped out because they had no improvement in their TD. The results were recalculated without these assumptions in order to test the sensitivity of the results.</P><P>We expected that many trials would use a crossover design. In order to exclude the potential additive effect in the second or more stages on these trials, only data from the first stage were analysed.</P><P>Dichotomous outcomes were analysed by calculating odds ratios for each trial with the uncertainty in each result being expressed using confidence intervals. The odds ratios from the individual trials were combined using appropriate methods of meta-analysis. When overall results were significant the number needed to treat to produce (or prevent) one outcome was calculated by combining the overall odds ratio with an estimate of the prevalence of the event in the control groups of the trials.</P><P>Continuous outcomes were analysed according to their difference in mean treatment effects and its standard deviation. Meta-analytical methods for continuous data assume that the underlying distribution of the measurements is Normal. The ratio of the mean to its standard deviation gives a crude way of assessing skew: if this ratio was less than 1.65 for any group in a trial and this can be resolved by log-transformation, the data then becoming normally distributed. It was proposed to undertake this procedure before including skewed data from any study in the analysis.</P><P>Heterogeneity in the results of the trials was assessed both by inspection of graphical presentations and by calculating a test of heterogeneity. Two possible reasons for heterogeneity were pre-specified: (i) that response differs according to different lengths of follow-up; (ii) that response differs according to the different drugs. These were assessed by looking at separate subgroups of trials [(i) and (ii)].</P></SUBSECTION></APPENDIX_BODY></APPENDIX></APPENDICES><EXTENSIONS><EXTENSION ID="FLOW_4" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART"><ALIAS ALIAS_ID="4"><FLOWCHARTBOX TEXT="&lt;p&gt;2 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;2 studies included in qualitative synthesis&lt;/p&gt;&lt;p&gt;1 study awaiting classification&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;31 full-text articles (25 studies) assessed for eligibility&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;725 records screened&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;725 records after duplicates removed&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;704 records identified through database searching&lt;/p&gt;" WIDTH="120"/><FLOWCHARTBOX TEXT="&lt;p&gt;13 additional records identified through searching reference lists of published Cochrane reviews on tardive dyskinesia&lt;/p&gt;" WIDTH="120"/><FLOWCHARTBOX TEXT="&lt;p&gt;8 records found from 2017 searching&lt;/p&gt;"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;694 records excluded&lt;/p&gt;" WIDTH="120"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;28 full-text articles (22 studies) excluded, with reasons&lt;/p&gt;" WIDTH="120"/></FLOWCHARTBOX></FLOWCHARTBOX></FLOWCHARTBOX></ALIAS></EXTENSION></EXTENSIONS></COCHRANE_REVIEW>